Skip to main content
PLOS One logoLink to PLOS One
. 2023 Nov 7;18(11):e0294048. doi: 10.1371/journal.pone.0294048

Testing biological actions of medicinal plants from northern Vietnam on zebrafish embryos and larvae: Developmental, behavioral, and putative therapeutical effects

My Hanh Tran 1,2, Thi Van Anh Nguyen 2, Hoang Giang Do 3, Trung Kien Kieu 4, Thi Kim Thanh Nguyen 5, Hong Diep Le 5, Gustavo Guerrero-Limon 1, Laura Massoz 6, Renaud Nivelle 1, Jérémie Zappia 1, Hai The Pham 2,4, Lai Thanh Nguyen 4, Marc Muller 1,*
Editor: Michael Klymkowsky7
PMCID: PMC10629648  PMID: 37934745

Abstract

Evaluating the risks and benefits of using traditional medicinal plants is of utmost importance for a huge fraction of the human population, in particular in Northern Vietnam. Zebrafish are increasingly used as a simple vertebrate model for testing toxic and physiological effects of compounds, especially on development. Here, we tested 12 ethanolic extracts from popular medicinal plants collected in northern Vietnam for their effects on zebrafish survival and development during the first 4 days after fertilization. We characterized more in detail their effects on epiboly, hatching, growth, necrosis, body curvature, angiogenesis, skeletal development and mostly increased movement behavior. Finally, we confirm the effect on epiboly caused by the Mahonia bealei extract by staining the actin filaments and performing whole genome gene expression analysis. Further, we show that this extract also inhibits cell migration of mouse embryo fibroblasts. Finally, we analyzed the chemical composition of the Mahonia bealei extract and test the effects of its major components. In conclusion, we show that traditional medicinal plant extracts are able to affect zebrafish early life stage development to various degrees. In addition, we show that an extract causing delay in epiboly also inhibits mammalian cell migration, suggesting that this effect may serve as a preliminary test for identifying extracts that inhibit cancer metastasis.

Introduction

In recent years, the pharmacological study of traditional medicine knowledge in plant research received considerable interest. Medicinal plants contain many phytochemicals such as vitamins, carotenoids, terpenoids, flavonoids, polyphenols, alkaloids, tannins, saponins, enzymes, and minerals that present biological activities on other organisms. They have antimicrobial activities, anti-inflammatory [1, 2], anti-hyperuricemic [3], antioxidant [4, 5] and anticancer properties [6]. Therefore, these phytochemicals have been utilized to prevent or cure a variety of disorders [7, 8].

Southeast Asia has one of the highest levels of biodiversity on the planet due to its complicated geological history. Geologic movements in the past, along with a tropical environment, aided speciation and formed in this region one of the most diverse biotas on earth. As a Southeast Asian country, Vietnam also possesses a diverse biota. In addition, with its land spanning a wide range of longitudes and various geological features, the natural environment in Vietnam provides a rich source of unusual and potentially intriguing biological components, many of which may be native to Vietnam and hence have not yet been documented elsewhere. On the scientific aspect, at present, the medicinal potential of this biological diversity is largely unexplored in Northern Vietnam. In this region, traditional medicine is mainly used locally for prevention and treatment of high frequency diseases, such as: infection, inflammation, immunological (including autoimmune) and heart disease, metabolic and neurologic disorders. Only some systematic reviews have been published of materials used in Vietnamese traditional medical practice [9, 10], and in Vietnamese [1114]. Traditional medicine mostly relies on experience passed on from one generation to the next to use specific plant extracts for certain pathologies. However, this practice suffers from the absence of systematic, interdisciplinary, large-scale, and comprehensive studies on the biological and pharmacological properties of the medicinal plants used. Furthermore, medicinal plants are often seen as “natural” products that may be administered for extended periods, occasionally resulting in severe adverse health outcomes. Further evidence-based studies and meta-analyses are required to provide a more objective assessment.

Zebrafish is commonly used as a vertebrate model organism [15] initially demonstrating its use in embryonic developmental biology but also increasingly in toxicology, pharmacology, and vertebrate behavioral biology in recent years [1618]. The zebrafish offers numerous benefits over traditional animal models (rabbit, rat, and mice) [2, 19]. First, although being a complete and independent life form, the zebrafish embryo up to the free-feeding stage at 5 days post fertilization is generally considered as larval stage; hence it can be used without raising ethical issues. Second, zebrafish are easy to maintain, and embryo yields are tremendous (50–300 embryos/pair/week). Third, the developmental process of a zebrafish embryo represents that of other vertebrates with highly similar embryogenesis and organogenesis, but much faster, which can be observed clearly through the transparent embryos [20]. Moreover, being one of the first sequenced and annotated genomes, the well-known zebrafish genome shares numerous similarities with higher vertebrates, including humans [21], especially in structure and function of certain CYP family genes involved in drug metabolism [22]. When these factors are considered together, zebrafish is a highly potent model for testing drug’s preclinical (developmental) toxicity today.

The "Zebrafish Embryo Toxicity" (ZET) test is included as an alternative to animal testing [23] and can be performed with a variety of endpoints [2426], which would be any "…biological or chemical process, response, or effect, as measured by a test." [27]. Within this scope, in this study, twelve medicinal plants from northern Vietnam were selected, based on traditional use as well as socio-economic issues, for a rapid screening test using the zebrafish model. Focusing on the first 5 days of development, we utilize this approach to evaluate effects on early embryogenesis, of particular interest when treating pregnant women, but we also rapidly assess many pathways and processes that may play a role in pathogenesis at later life stages of crude extracts obtained from the six most promising plants. Finally, the effect on epiboly of the Mahonia bealei extract was further investigated and an effect on mammalian cell migration was confirmed. First tests investigating major purified chemical components of this extract were also performed.

Materials and methods

Plant material

Medicinal plants (Table 1) were selected based on the recipes of traditional medicines and collected from the North-Western mountainous areas of Vietnam in the dry season of 2019. They were identified, coded (with Vietnamese and Scientific names) and placed at the Museum of Biology, Faculty of Biology, VNU University of Science, Vietnam National University, Hanoi, Vietnam.

Table 1. Medicinal plants used for toxicity screening.

Label/Code Scientific names (Vietnamese name) Voucher number Sampling: GPS coordinates, province, date collected Parts of interest
KT02 Lactuca indica L. (Bo cong anh cao) HNU 024108 21°00’57.3"N 107°19’02.6"E (Lạng Giang, Lạng Sơn); spring 2019 Fresh stem
KT06 Anisomeles indica (L.) Kuntze (Phong phong thao) HNU 024777 22°26’18.7"N 103°55’25.9"E (Bat Xat, Lao Cai); fall 2017 Dry stem/ leaves
KT07 Clerodendrum cyrtophyllum Turcz. (Bo may) HNU 024106 22°26’06.7"N 104°57’55.1"E (Bac Quang, Ha Giang); fall 2017 Dry leaves
KT08 Pericampylus glaucus (Lam.) Merr. (Tiet de la day) HNU 024778 22°26’18.7"N 103°55’25.9"E (Bat Xat, Lao Cai); fall 2017 Dry leaves
KT09 Mahonia bealei (Fortune) Pynaert (Hoang lien) HNU 024779 22°34’01.5"N 103°46’47.9"E (Bat Xat, Lao Cai); fall 2017 Dry stem
KT11 Gnetum montanum Markgr. (Day gam nui) HNU 024781 22°34’47.0"N 105°06’39.8"E (Vi Xuyen, Ha Giang); summer 2017 Dry stem
KT12 Tacca chantrieri André (Rau hum hoa tia) HNU 024782 22°34’47.0"N 105°06’39.8"E (Vi Xuyen, Ha Giang); fall 2018 Dry stem
KT14 Mallotus barbatus Müll.Arg. (Bum bup) HNU 024784 20°32’02.6"N 105°23’55.8"E (Lac Son, Hoa Binh); summer 2017 Dry root
KT15 Aganope balansae (Gagnep.) P.K.Loc (Man man) HNU 024785 22°26’06.7"N 104°57’55.1"E (Bắc Quang, Hà Giang); fall 2018 Dry stem
KT17 Stixis scandens Lour. (Trung cuoc) HNU 024787 22°26’06.7"N 104°57’55.1"E (Bắc Quang, Hà Giang); fall 2019 Dry leaves
KT19 Croton kongensis Gagnep. (Kho sam) HNU 024789 20°32’02.6"N 105°23’55.8"E (Lac Son, Hoa Binh); fall 2017 Dry leaves
KT20 Tinospora sinensis (Lour.) Merr. (Day dau xuong) HNU 024790 20°32’02.6"N 105°23’55.8"E (Lạc Sơn, Hòa Bình); fall 2018 Fresh stem

Preparation of plant extracts

Dried plant powders were used for extraction with ethanol solvent. Each dried powder sample was suspended with solvent at the ratio of 1:10 (w/v) and placed into an ultrasonic incubator (S100H; Elma GmbH, Singen, Germany) for 30 min at 45°C. The mixture was shaken at 200 rpm for 60 min at room temperature in an orbital incubator shaker (Gyromax™ 747 Incubator Shaker; Amerex Instruments, Concord, CA USA). The supernatant was separated from the plant residues by centrifugation (Avanti J-E; Beckman Coulter, Brea, CA USA) at 10000 rpm for 20 min at 10°C, then filtered through Whatman No. 1 filter paper; the obtained filtrate was dried completely in a vacuum rotary evaporator (HS-2005S-N, Hahnshin, Gimpo, South Korea). The dried extracts were stored at 4°C. Just before experimentation, the extracts were dissolved in dimethyl sulfoxide (DMSO) to obtain stock solutions, which were then diluted to different concentrations for further analyses.

Zebrafish maintenance

Animal care and all experimentation were conducted in compliance with Belgian and European laws (Authorization: LA1610002). All experiments and the entire study were evaluated by the Ethical Committee of the Université de Liège, Belgium and the study protocols were approved under the file numbers 1076 and 13–1506. Zebrafish (Danio rerio) of the AB strain and the Tg(fli1:EGFP) [28] transgenic line were obtained from breeding facilities at the GIGA-Institute, Liege, Belgium. The water characteristics were as follows: pH = 7.4 and temperature = 28°C. The lighting was 14/10-h light/dark. Embryos were used and staged as described [29, 30]. Fish were mated and spawning was stimulated by the onset of light. The day before breeding, adult male and female zebrafish were set up in several breeding tanks, separated by a clear plastic wall. After the light was turned on the next morning, walls were removed, natural mating occured and the eggs were collected between 30 minutes to 2 hours after spawning. After sorting, fertilized clean eggs are moved to Petri dishes and incubated at 28°C in E3 medium (5 mM Na Cl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4, 0.00001% Methylene Blue). The age of the embryos and larvae is indicated as hours post fertilization (hpf) [31].

Medicinal plant extract exposure

The plant extract solutions at different concentrations for toxicity tests were obtained by dilution of the stock solutions in embryo medium (E3). Treatments were administered starting at 2 hpf to zebrafish embryos distributed in pools of 25 individuals into 6-well plates in E3 medium until 120 hpf. The larvae were rinsed every 24 hours in E3 until 96 hpf and the treatments were renewed each day using a freshly prepared plant extract solution to maintain oxygen and nominal concentrations constant during the assay and to remove fungi or other organisms that could develop in the dish [32]. Untreated control batches received only the E3 with 0.5% DMSO used for the stock solutions. Three independent biological replicates were run for each concentration of plant extracts and controls. The ranges of concentrations were selected based on the results of the preliminary test which identified a concentration to induce death and morphological defects. The larvae were rinsed twice in E3 before observation, survival and morphological/ developmental defects were assessed using a Leica M165 FC stereomicroscope (Leica Microsystems©, Wetzlar, Germany). Developmental morphological abnormalities were recorded as the numbers of larvae presenting at least one morphological defect by using parameters such as retardation, spinal curvature, yolk sac edema, delay in pigmentation and hatching delay [33]. Experiments having more than 5% abnormal development in the controls were discarded. Each treatment group was analyzed without preconception, especially regarding the specific defect observed.

Angiogenic effects analysis

To assess the anti-angiogenic potential of the plant extracts, we used the transgenic Tg(fli1a:EGFP) zebrafish that continuously express the green fluorescent protein EGFP under control of the fli1 promoter in the endothelial cells (which make blood vessels) [28]. The embryos were exposed to sub-LC10 values of plant extracts, to check the activity of medicinal plants on angiogenesis. After 24 hpf, the embryos were incubated in a pronase solution (2mg/ml) at room temperature typically for 3–5 minutes. For mechanical dechorionation, the embryo suspension was pipetted back and forth using a Pasteur pipet [34] before thorough washing (3 or 4 times) in E3 medium to remove pronase. The released embryos were then exposed to the plant extracts and examined at 72 hpf [35] using a Leica M165FC stereomicroscope for the presence and the number of ectopic vessels in the sub-intestinal vessel (SIV) region as an indication of pro-angiogenesis effects [36]. The mean sprout number was assessed by the sum of the number of sprouts present in each sample group over the total number of embryos in the sample group. Sprout intensity of the sample group was rated as “+”, “++”, and “+++”, representing the percentage of embryos with one, two, and three or more sprouts in the SIV regions, respectively. Images were processed using the ZEN software (Zeiss, Jena, Germany).

Cartilage staining

Alcian blue staining was used for optimal visualization of cartilage structures in the head of the embryos (head malformations) as described in previous studies [37, 38]. At 120 hpf, the larvae were sacrificed with Tricaine. The exposure medium was then removed, and the larvae were fixed with 4% paraformaldehyde in PBS solution (4% PFA-PBS) at 4°C overnight. The larvae were rinsed 3 times with PBST during 10 mins, then were stained with 0.04% Alcian blue in 80% ethanol with 20 mM MgCl2 overnight. Background of the staining was removed by washing with 80% ethanol/20 mM MgCl2/water several times. After that, bleaching was conducted by adding 1 ml of H2O2 3%/KOH 0.5% during 20–60 mins. The larvae were then rinsed with graded concentrations of glycerol in KOH: 25% glycerol/0.1% KOH and 50% glycerol/0.1% KOH and kept in this solution for storage [39]. The cartilage-stained larvae were transferred and embedded on slides in the correct orientation (ventral-up position for pharyngeal cartilage and dorsal-up position for other craniofacial elements) with absolute glycerol and photographed using a digital camera mounted on an Olympus SZX10 stereomicroscope (Olympus, Antwerp, Belgium).

Behavior analysis

Behavioral tests were conducted on zebrafish larvae at > 98 ~ 120 hpf and every test was performed between 10:00 to 13:00 to maintain a constant position in the circadian cycle. Prior to each behavioral test, the zebrafish larvae were inspected under a stereomicroscope to select and transfer to the testing plates only individuals devoid of any malformation that might interfere with mobility outcome (e.g. yolk sac or pericardial edemas, spinal aberrations, aberrations in pigmentation, and/or loss of equilibrium, etc). The treated larvae were transferred to 96-well microplates with one embryo in each well containing 100 μl of E3 medium (24 embryos per group). Movements of exposed and control individual larvae were recorded using a ViewPoint® Zebrabox system and its tracking software (ViewPoint Life Sciences, Lyon, France). The light level was set to 20% on the ViewPoint software (7.45 Klux, TES 1337 light meter), while infrared light (850 nm) was used to track larval activity. We used an assay with alternating, 10 min light and 10 min dark cycles to study the dynamics of the photo-motor response in different light and dark phases during the experiment. The locomotion measurements were assessed for 1 hour by recording free swimming activity, swimming distances and speeds. In the first 20 min., the larvae were kept in the light for habituation, while the recordings were discarded from the analysis, then they were subjected to two cycles of alternating 10 min. dark and light periods to record their swimming behavior. The video and tracking software was set to screen larval locomotion behavior in 30 seconds intervals, the "distance travelled" and the "time spent active" were determined and, from these parameters, the mean swimming speed was also calculated by dividing the cumulated distance travelled by the total time spent active.

Cell culture and in vitro wound healing

Mouse Embryonic Fibroblasts (MEFs) (STO: CRL-1503) were grown in DMEM-HG (D-7777, Sigma) supplemented with 10% FBS (v/v) and 1% antibiotics (50 U/ml penicillin– 50 ug/ml streptomycin. A cell viability/proliferation test based on the detection of ATP produced by viable cells (CellTiter-Glo™ Luminescent Cell Viability Assay Kit; Promega) was performed using the limit test to find the maximum concentration having no effect (the NOEC) and the lowest concentration having an effect (LOEC).

The in vitro scratch assay was performed on MEF cells to examine wound-healing capacity as previously reported [40, 41]. MEFs were seeded into 24 well plates and grown until reaching 80% confluence. Scratches (0,6 ± 0,05mm) were made using SPL ScarTM Scratcher (SPL Life Sciences, Pocheon, South Korea) and cells were washed with PBS twice to ensure there were no cells within the scratch area. As the extracts were dissolved in DMSO, DMSO 0.1% was added to the medium DMEM-HG + 10% FBS (v/v) + 1% antibiotics (50 U/ml penicillin– 50 ug/ml streptomycin) with β-Mercaptoethanol as the negative control. Scratches were photographed under the microscope immediately after scratching and after 12h, 14h, 18h and 22 h (until the scratches in the control wells were restored to about 100%) incubation at 37°C in a 5% CO2 incubator to document the wound-healing process. The images were processed using the Macro "MRI Wound Healing Tool" of ImageJ software to determine the areas of the wounds at the marked location over various time frames to evaluate the influence of the extract on the cellular wound healing capacity. We used the following formula:

Woundarearecoveryrate(%)=(1scratchareaatspecifictimescratchareaat0thhour)x100%

F-actin staining

Wildtype embryos at 8 hpf (70% epiboly stage) were fixed in 4% paraformaldehyde (PFA) in PBS at 4°C overnight, and then washed 3 times with 0.1% Tween-20 PBS for 5 min each. After washing, unspecific sites were blocked with 4% BSA in PBS for 1 hour at 4°C, then rinsed with PBS. Afterward, the embryos were incubated with phalloidin-Atto 532, a high-affinity probe for F-actin (Merck, Darmstadt, Germany) for 1 hour at 4°C, then washed 3 times for 5 min each time with PBS. Subsequently, they were mounted on Vectashield mounting media (Prolong Gold antifade®, Invitrogen, Waltham, MA USA), imaged under a Leica SP5 confocal microscope (Leica, Wetzlar, Germany), and processed using LSM software. The figures were assembled using Image J (NIH, Bethesda, MD USA).

RNA extraction

RNA was extracted from pools of 75 larvae using the RNA mini extraction kit (Qiagen, Hilden, Germany). We chose to use whole larvae, including the yolk, as we intended to determine the entire RNA pool for evaluation of transcription, but also maturation and degradation. Samples were lysed in RLT+ buffer with β-mercaptoethanol (Sigma-Aldrich, Overijse, Belgium) and homogenized 10 times with a 26-gauge needle in a 1 ml syringe. 22 μl of RNAse free water were used to resuspend total RNA. RNA extract was treated with DNAseI (Qiagen, Hilden, Germany) to avoid DNA contamination. The quantity (ng/μl) and quality of each extract was assessed by nanodrop spectrophotometer measurements (Thermofisher Scientific, Waltham, MA USA). Poor quality (260/280 < 2; 260/230 < 2) samples were subsequently purified by Lithium chloride precipitation, followed by 2 times pellet washing with 70% ethanol and resuspended in 40 μl of RNAse-free water and stored at -80°C. The integrity of total RNA extracts was assessed using a BioAnalyzer (Agilent, Santa Clara, CA USA) providing RIN (RNA Integrity Number) scores for each sample.

RNA sequencing

cDNA libraries were generated from 100 to 500 ng of total RNA using the Illumina Truseq mRNA stranded kit (Illumina, San Diego, CA USA) according to the manufacturer’s instructions. cDNA libraries were then sequenced on a NovaSeq sequencing system, in 1 x 100 bp (single-end). Approximatively 20-25M reads were sequenced per sample. The sequencing reads were processed through the Nf-core rnaseq pipeline 3.0 [42] with default parameters, using the zebrafish reference genome (GRCz11) and the annotation set from Ensembl release 103 (www.ensembl.org). Differential gene expression analysis was performed using the DESeq2 pipeline [43]. Pathway and biological function enrichment analyses was performed using the WEB-based "GEne SeT AnaLysis Toolkit" (http://www.webgestalt.org) based on the integrated GO (Gene Ontology), KEGG (Kyoto Encyclopedia of Genes and Genomes) [44, 45], Panther and WikiPathways databases. An additional database was constructed using the Gene-mutant/Phenotype database from zfin (zfin.org).

Identification of alkaloids from M. bealei ethanolic extract

The alkaloid components from M. bealei ethanolic crude extract were identified by the HPLC-DAD method. 9 reference compounds, including jatrorrhizine, isotetradine, 3-hydroxy-8-oxopalmatine, 8-oxypalmatine, oxyberberine, rugosinone, 8-oxyberberubine, berberine, palmatine, were collected from the in-house library of the "Center for Research and Technology Transfer, Vietnam Academy of Science and Technology". HPLC-grade solvents were purchased from Scharlau (Barcelona, Spain) and Merck Millipore (Darmstadt, Germany). HPLC-DAD data were generated on a Thermo Ultimate 3000 system, consisting of a quaternary pump, an autosampler, a column oven, and a diode array detector. A Hypersil GOLD HPLC column (250 mm x 4.6 mm, 5 μm) was used at 40°C. The solvent conditions were optimized to detect as many compounds as possible, specifically potassium phosphate buffer (10 mM, pH 5.0) and acetonitrile (0.1% of acetic acid) were set as solvent channels A and B, respectively. A flow rate of 1.0 mL per min was selected with a linear gradient from 20% to 80% B over 20 min, followed by 5 min washing with 80% B and 5 min of the initial condition. The injection volume for each sample was 5 μL. The UV detector was set at 270 nm for the simultaneous determination of 9 standard compounds. The compounds were detected in the extract by comparing their retention times and UV spectra to those of the reference compounds which were analyzed under the same condition. Berberine and palmatine were purified as previously described [46].

Data and statistical analysis

All experiments were performed at least three times, mostly on different dates but always on different clutches from different parents. Statistical analyses were performed using GraphPad Prism for Windows (version 8.0.1) using the appropriate tests as indicated. LC50, LC10, EC50 and EC10 were calculated by plotting the surviving/affected larvae against the log transformed tested concentration and the obtained curve was fitted to a sigmoidal concentration–response relation according to the following equation:

y=Bottom+(TopBottom)1+10logEC50x

where bottom and top represent, respectively, the lowest and the highest y-value (% survivors/affected). The resulting calculated log EC/LC were extracted, and their corresponding 95% Confidence Intervals (C.I.) are given.

Raw behavioral data sets consisted of tables holding the positions of each larva in each video frame (30 frames/second). This table was first cleaned to eliminate very short, oscillating and likely artefactual movements, and then aggregated into 30-second periods for further analysis. These data were transferred to R version 4.0.2 [47] to analyze motility during the dark and light phases. To assess behavior, we used linear mixed effect (LME) models within the “nlme” package. Three dependent variables were used, either the "mean time spent active" (seconds), the "mean distance travelled" (mm), or the "mean swimming speed" (calculated as the mean distance travelled/mean time spent active) within each 30 second period, with "compound" as the categorical independent variable, and batch as a random effect. The “Anova” command within the “car” library was used to extract the results for the main effects whereas the “lsmeans” command within the “emmeans” library was used as a post-hoc test to compare groups against one another while adjusting for the means of other factors within the model [48]. Type II sum of squares was used for the model. Significance was assigned at p = < 0.05.

Results

Effects of medicinal plant extracts on survival and malformation of zebrafish embryos

Ethanol extracts from 12 medicinal plants collected from Northern Vietnam were examined according to the zebrafish embryo toxicity test [49]. To assess the survival and developmental defects caused in the zebrafish embryos/larvae by exposure to plant extracts, embryos were treated with a range of concentrations based on a preliminary, range-finding test for each extract starting at 2 hpf and assessed every day until 96 hpf for lethality and occurrence of morphological defects (Table 2).

Table 2. Calculated toxicological indices for all 12 studied extracts.

Code of extract LC50 (μg/mL) EC50 (μg/mL) TI
24h 48h 72h 96h 24h 48h 72h 96h 96h
KT02 >2000 >2000 437–508 246–255 547–724 216–234 202–214 203–209 1.22
KT06 248–420 181–270 175–271 171–262 No defects 105–215 125–279 1.14
KT07 599–770 430–738 335–444 236–294 273–1411 132–235 94–101 48–71 4.59
KT08 466–682 471–613 390–604 460–571 No defects 206–685 218–391 1.73
KT09 243–313 226–277 181–191 128–132 173–198 106–147 53–75 56–63 2.20
KT11 262–296 250–278 232–257 138–144 270–314 173–186 97–123 77–83 1.76
KT12 94–104 79–107 70–91 68–91 No defects
KT14 >2000 >2000 267–1202 178–192 502–519 236–253 253–316 228–257 0.76
KT15 250–267 227–244 202–224 164–169 295 180–192 114–124 98–113 1.57
KT17 1631–2082 1553–1779 1470–1691 1309–1413 No defects 844–1113 707–915 555–827 2.03
KT19 148–274 142–274 105–189 103–161 >2000 >2000 155 88–146 1.08
KT20 552–629 373–425 365–418 365–418 540–682 322–452 304–340 271–403 1.17

The calculated log EC/LC are shown as their corresponding 95% Confidence Intervals (C.I.) are given. Rare or irreproducible phenotypes were ignored. Teratogenic Index (TI) at 96 hpf highlighted in grey, selected extracts in bold.

For all the tested plants, we were able to define lethal concentrations, with only KT12 presenting an LC50 below 100μg/mL which would classify it as toxic [49], while KT17 was the least toxic extract (LC50 > 1.3 mg/mL at all stages). In terms of developmental defects, KT17 stood out again with the highest EC50 for any observed defect, while KT09 and KT07 presented the lowest EC50 at 72 and 96hpf. These three extracts also showed the highest teratogenic indices (TI), either due to the low lethal effect (KT17) or to the strong effect on embryogenesis. KT12 extract caused no developmental defects, due to its high level of toxicity. Based on these screening results, we decided to focus on a group of plants that all caused developmental effects but covering a range of EC50 and LC50 values (KT02, KT09, KT11, KT14, KT15, KT20), to determine the specific defects they cause, starting at early stages and at concentrations around LC0, LC10 and LC25 for each extract (Fig 2).

Fig 2. Morphological defects at different time points of exposure.

Fig 2

A-F: Representative images of 4–96 hpf larvae exposure to 6 plant extracts at the indicated concentrations. The morphology of embryos was observed and captured under a stereomicroscope. Scale bars = 400 μm. Green arrows indicate dumb-bell shape yolk, blue arrows indicate dorsal curvature, pink arrows indicate yolk sac edema, red arrows indicate hemorrhage orange arrows indicated necrosis, and stars indicate delayed hatching.

While no effect on survival or malformation was observed at any time point following exposure to 0.5% DMSO, the highest concentration of solvent used in these experiments, exposure of zebrafish embryos to medicinal plant extracts resulted in decreased survival depending on the concentration of the specific extract. Survival rates were analyzed for several concentrations and LC50 was determined for each extract (Table 2). The lethal toxicity was gradually increased from KT20, KT02, KT14, KT15, KT11, to KT09 extracts, based on LC50-96h, as summarized in Table 2 and Fig 1. The results of lethal concentrations clearly show that all the compounds are lethal to zebrafish larvae at various concentrations. With the possibility to observe early developmental effects during the first 4 days, we concentrated on perturbations such as dorsal curvature, yolk sac edema, hemorrhage, delayed hatching, or altered size. The fraction of the surviving embryos presenting any of the above-described morphological abnormalities was determined for the different concentrations of each extract (Fig 1). The teratogenic Index (TI) steadily increased from KT14, KT20, KT02, KT15, KT11, to KT09 extracts (Table 2). All extracts have TIs greater than 1, with the exception of KT14, indicating that all of these chemicals have the potential to cause abnormalities in zebrafish embryos. The TI of KT14 is less than 1, suggesting that this is a milder teratogenic agent for fish embryos and typically surviving embryos/larvae would not have deformities.

Fig 1. Survival and morphological defects of larvae after exposure to medicinal plant extracts.

Fig 1

Fraction of surviving larvae or larvae presenting any morphological defect at 96 hpf upon exposure to KT02 (A), KT09 (B), KT11 (C), KT14 (D), KT15 (E) and KT20 (F). Experiments were performed at least in triplicate with each time n = 50 larvae per point. Fraction of larvae presenting any morphological defects are represented in dotted lines.

Morphological effects of six medicinal plant extracts on zebrafish embryos

Representative images are given for the various concentrations of each extract (Fig 2). In general, the effects of all extracts are dose-dependent (Fig 2 and Table 3): not only did the proportion of dead and malformed embryos increase with increasing concentration, but so did the severity and complexity of phenotypes–as evidenced by the number of phenotypes and the fraction of mixed or multiple phenotypes (Table 3), particularly in severely deformed embryos. Furthermore, the severity of specific traits increased (e.g. bigger edemas, more strongly curved tail, or darker yolk necrosis) (Table 3). Embryos and larvae exposed to extracts at high concentrations, near the LC50 had significant systemic morphological abnormalities.

Table 3. Frequencies of specific defects caused by 6 plant extracts (numbers were recorded at the concentrations of LC10 and LC25).

Defects Control KT02 KT09 KT11 KT14 KT15 KT20
LC10 LC25 LC10 LC25 LC10 LC25 LC10 LC25 LC10 LC25 LC10 LC25
Dumb-bell shaped yolk (10hpf) 3/150 17/150 47/150 31/149 65/147 19/149 43/147 17/150 44/149 18/150 50/149 11/150 32/149
Oedema (>24 hpf) 2/147 9/137 55/115 18/141 55/117 23/138 50/116 9/135 21/112 29/141 51/113 11/141 29/120
Necrosis (72/96hpf) 0/147 2/137 17/115 5/141 52/117 17/138 50/116 27/135 45/112 16/141 48/113 5/141 15/120
Hemorrhage (72/96hpf) 0/147 0/137 5/115 3/141 9/117 0/138 5/116 3/135 7/112 0/141 1/113 0/141 0/120
Curvature (72/96 hpf) 1/147 5/137 19/115 7/141 20/117 3/138 8/116 10/135 31/112 9/141 30/113 19/141 41/120
Hatching delay (72/96 dpf) 2/147 0/137 24/115 31/141 56/117 41/138 62/116 0/135 4/112 2/141 5/113 0/141 0/120

A noteworthy feature observed was that all the extracts generated dumbbell-shaped yolk embryos at the stage of 8–10 hpf, as best illustrated by the KT09 extract which had the highest incidence (Fig 2B and Table 3). It began with the presence of a dumbbell-shaped yolk between 8 and 10 hpf, followed by a clear delay in development at 1dpf that increased with increasing extract concentration. At 2 and 3dpf, the most striking feature was a delay in hatching, while in 3 and 4dpf larvae the lower concentrations of treatment induced some local malformations such as yolk sac edema and curvature in the surviving larvae. The survival rate of embryos declined strongly within the first 24 hours (S1 Fig). We also find the presence of a dumbbell-shaped yolk and hatching retardation when embryos are exposed to a high concentration of KT11 extract. In addition, the KT11 extract caused an even stronger delay in hatching; the embryos did not hatch after 4 days, and some of them died inside the chorion. The survival rate of embryos was reduced at 24hpf, constant until 72hpf, and reduced again at 96hpf (S1 Fig), implying that this extract causes death at an early stage (before 24hpf) and again later, possibly due to the hatching delay. RNA-Seq analysis at different time points would help to understand the mechanisms involved. The presence of dumbbell-shaped yolk after KT14 extract treatment was observed at 200 μg/ml and 10hpf, however it appears to be recovered at later stages, as no hatching or developmental delay was seen at 24 or 48hpf. Intriguingly, lethality of this extract increased dramatically at 72 hpf (S1 Fig), after hatching, implying that the chorion plays a protective role against its toxicity. At high concentrations, the KT15 extract caused developmental delay and after three days of exposure, this extract was highly toxic to embryos. The treated embryos displayed substantial defects, such as edema, altered size, and necrosis, which could lead to mortality in a later stage. This finding explained why the survival rate of embryos was lower after 72 hours of treatment. KT02 and KT20 extracts appear to be safer and produce fewer abnormalities than the other extracts in the group; nevertheless, some defects were noticed at high concentrations of these extracts. Embryos exposed to KT02 had a lower survival rate after 48 hours, and embryos exposed to KT20 had a lower survival rate after 24 hours (S1 Fig).

Effects of six medicinal plant extracts on angiogenesis in zebrafish larvae

Angiogenesis plays an important role in a wide range of physiological processes such as wound healing and fetal development. In fact, many diseases are associated with an imbalance in the regulation of angiogenesis in which there is either excessive or insufficient blood vessel formation. The fact that some extracts caused a hemostasis phenotype in larvae prompted us to investigate their anti-angiogenic properties. To that end, the zebrafish transgenic line Tg(fli1:EGFP) (y1Tg) displaying fluorescent endothelial cells was used to visualize blood vessels and detect effects on angiogenesis. In zebrafish, a basal blood circulatory loop is set up at 24hpf, then angiogenic vessel development extends the system, including the sub intestinal vessels (SIVs) at 72hpf. We thus investigated the effect of six plant extracts on changes in SIV development at 72hpf.

Six plant extracts were shown to promote changes in SIV formation to various degrees, at exposure concentrations substantially lower than the corresponding LC10. The most striking feature we observed was the formation of longer, more numerous, and ectopic sprouts projecting outwards from the sub intestinal vessel basket (ramification). We classified the individuals according to their SIV formation from WT (-) through increasing levels of ectopic sprouts (+, ++, +++,…) (Fig 3B) to formation of hemorrhagic patches (Fig 3A). Looking at the frequency of embryos with varying degrees of ectopic sprouts in the SIVs (percentage of abnormal phenotypes) when exposed to increasing concentrations of each plant extract, it appears that the treatment with KT11 and KT14 trigger the most ectopic angiogenesis of SIVs compared to controls, followed by exposure to KT09 and KT02. These defects worsened in a dose-dependent manner. On the other hand, KT15 and KT20 extracts generated ramifications in the SIVs basket, but the data collected did not reveal concentration dependence of this effect.

Fig 3. The effects of six plant extracts on blood vessel formation in SIVs of Tg (fli1: EGFP) zebrafish larvae.

Fig 3

(A) Hemorrhage (white arrow) was observed in 3 dpf zebrafish larvae treated with KT14 150 μg/mL. (B) Microscopic view of blood vessel formation of zebrafish at 72 hpf in the absence and presence of ectopic angiogenesis of Sub intestinal vessels (SIVs), SIVs are marked by a red frame and shown at a higher magnification. The number of “+” is the number of sprouts projecting from the SIVs basket. (C) Quantitative analysis of the percentage of each angiogenic phenotype in SIVs after treatment with the different plant extracts. Sample groups were assessed according to “+”, “++”, “+++”, “++++” and “+++++” representing the percentage of embryos with one, two, three, four or five sprouts projecting out of the SIV regions, respectively. Images were taken using ZEN software. Data present mean ± SD from three independent experiments. Statistical analysis was performed using a two-way ANOVA test, p-values < 0.05 *; 0.01 **; 0.001***.

Effects of six medicinal plant extracts on cartilage formation in zebrafish larvae

The early development of the head skeleton depends on many regulatory pathways, such as Wnt, Bmp, Hh signaling that are also involved in other developmental processes [50]. Malformations of the head are among the teratological effects induced by plant extracts. Therefore, we performed a more thorough analysis of effects on the head skeleton through enhanced visualization by staining of the cranial cartilage. We employed the Alcian blue dye, which can specifically combine with the cartilage matrix and thus visualize cartilage structures [51]. Whole-mount Alcian blue staining revealed that the head cartilage at 120 hpf had a different pattern in larvae treated with each plant extract at the concentration of LC10 as compared to the control. The skull and pharyngeal cartilage structures in the control group had completely developed (Fig 4A), while in the treated groups, effects ranged from nearly absent (B) to lightly stained (C) cartilage, a shorter chondrocranium compared to the control group (B, C, F), to severely deformed cartilage elements (E, G) indicating that medicinal plant extracts hindered the differentiation of chondrocytes and thus induced decreases in chondrocyte number, cartilage matrix secretion and lead to morphological alterations (Fig 4A–4E).

Fig 4. Medicinal plant extracts exposure affects head cartilage formation in zebrafish larvae.

Fig 4

Whole-mount preparations of the larva expose to extract of KT02 (B), KT09 (C), KT11 (D), KT14 (E), KT15 (F) and KT20 (G). (A) Control. Scale bar: 200 μm. (H) Statistical analysis of jaw malformations as categorized into different classes. Class 1: No observable change (Control); Class 2: Weak staining in P1 to P7 region and ethmoid plate; Class 3: Shortened jaw structure (P1, P2 and ep); Class 4: Severe structural changes in all regions; and Class 5: strongly reduced or loss of all regions. Data from three independent replicates are presented as bar graph. Abbreviations: P1: Meckel’s cartilage and palatoquadrate; P2: ceratohyal; P3-P7: ceratobranchial, and ep: ethmoid plate. Statistical analysis was performed using a two-way ANOVA test, p-values relative to control were always< 0.0001.

Based on the staining observed of the pharyngeal arches (P1: Meckel’s cartilage and palatoquadrate; P2: ceratohyal; P3-P7: ceratobranchial) and the ethmoid plate (ep) structure (Fig 4), we divided the deformities into 5 classes (Fig 4H). Class 1: No observable change (Control); Class 2: Mild staining in P1 to P7 region and ethmoid plate; Class 3: Shortened jaw structure (P1, P2 and ep); Class 4: Severe structural changes in all regions; and Class 5: strongly reduced or loss of all regions. Statistical analysis revealed that each extract’s influence on zebrafish cranial cartilage formation was significant (p<0.0001), it increased from KT11, KT14, KT09, KT02, KT20 to KT15 extracts. When exposed to KT11 and KT14 extracts, the percentage of larvae categorized as Class 1 (without any observable changes in Alcian blue staining) was still roughly 50% of the total larvae (Fig 4H), while it decreased to 8% upon KT15 exposure. Treatment with KT11, KT14, and KT09 only caused Class 2 and 3 malformations, whereas KT20 and KT15 generated significant proportions of severely malformed larvae (Class 4). For those larvae with shorter P1, P2, and ep (class 3), the head shape is clearly shorter (and more rounded) than the control at 120 hpf when viewed laterally (KT09 and KT14). Strong staining and extreme malformation of the chondrocranium, particularly the Meckel’s and ceratohyals, were observed in larvae treated with KT20 (Fig 4G), while in contrast KT02-exposed larvae had a significantly higher proportion of larvae with nearly no Alcian blue staining compared to controls or to those exposed to other extracts.

Effects of six medicinal plant extracts on locomotor activity of zebrafish larvae

To investigate possible effects of the plant extracts on zebrafish behavior, which might indicate modifications of neural development, we exposed zebrafish embryos/larvae to the plant extracts during 5 days before analyzing their motor behavior using an alternating 10 minutes dark and light protocol. In this type of test, it is known that zebrafish larvae are much more active in the dark, thus we observed a significantly increased time spent active, distance travelled and swimming speed during the dark phases for most of the conditions (Fig 5).

Fig 5. Locomotor behavior of larval zebrafish following exposure to various plant extracts for 5 days.

Fig 5

The records of larval motion are shown in 30 second intervals over one cycle of a 10 min dark- 10 min light photoperiod. (A) Free swimming distance recorded during 10 min in the dark, followed by 10 min in the light. (B) Time spent active during 10-min intervals for each light state (dark or light). (C) Free swimming speed over 20 min of one dark- to-light cycle. Data are expressed as the mean ± SEM of three replicates (24 larvae per replicate). The asterisk represents a statistically significant difference when compared with the controls as described in Mat. and Meth.; * at p < 0.05, ** at p < 0.01 and **** at p < 0.0001 levels.

Upon exposure to plant extracts, we observed changes in swimming activity between the treated and control groups in both dark and light periods, as shown in Fig 5. Under the 10-min dark and 10-min light cycle alternate stimulation, 5 out of 6 plant extract-treated groups showed significant increases of swimming distance, time and speed in dark conditions compared to the control group, only the KT09 extract exposure significantly decreased the activity of larval zebrafish in the dark. The KT20 extract exposure group exhibits the largest increase in swimming behavior when compared to other extracts, in both the dark and light phases, followed by KT02. This observation suggests that these extracts may cause hyperactivity.

As mentioned above, the locomotor activity of the larvae in general was higher during the 10 min dark phase, compared to the light phase. An interesting exception is the group exposed to KT09, where the swimming distance, time, and speed did not differ dramatically between the two periods. We wondered whether this effect could be due to impaired vision in this group. However, when we look at the rapid transition moments from dark to light or the reverse transition from light to dark, respectively, we observe a "startle" peak especially in the swimming speed (Fig 5C). This peak is seen in control larvae, and in larvae treated with KT15 and KT09, indicating that these larvae do respond to, and thus perceive the change in lighting. The absence of such a peak in larvae treated with KT20 and KT02 may be due to their increased activity in the dark phase, while KT11- and KT14-exposed animals appear to be more tolerant to these surprising changes.

Early developmental effects of the Mahonia bealei (KT09) extract

Effect of M. bealei (KT09) extract on epiboly process

Epiboly is characterized by spreading of the cell mass over the yolk sac—an important process that plays a prominent role in embryo gastrulation and specification of the dorsoventral axis [20, 52]. It is the first morphogenetic movement in zebrafish and amphibian embryos, leading to the expansion of blastoderm/ectoderm cells along the animal-vegetal axis, thereby covering the yolk cells and closing the blastopore. The early feature of dumbbell-shaped yolk at 8 and 10 dpf caused more prominently by the KT09 extract could be best explained by a delay in the process of epiboly, where several layers of embryonic cells move towards the vegetal pole to finally nearly cover the entire egg. Epiboly depends on the dynamic regulation of the actin cytoskeleton, the process of extensive cell movements involves intracellular actin filaments and their associated myosin motor proteins [53]. Cortical F-actin is organized in the enveloping layer (EVL) cells at the start of blastodisc flattening. Later in epiboly, a punctate marginal actin ring appears ahead of the leading edge of external yolk syncytial layer (E-YSL), and F-actin is present in the vegetal cortex of the yolk cell [54]. We therefore decided to further characterize this defect by following epiboly progression of blastoderm cells using phalloidin staining of filamentous actin (F-actin) fibers. At 9 hpf, when control embryos reached 90% epiboly, a regular and strong cortical F-actin was observed in EVL cells, while the vegetal cortex F-actin [55] formed bundles aligned along the animal-vegetal direction in the vegetal cortex of the yolk cell (Fig 6A). In addition, a strong F-actin ring was formed ahead of the leading edge of E-YSL (Fig 6A–6A”). KT09 extract (100 μg/mL) treatment resulted in a strongly reduced cortical F-actin in the EVL and a weak actin ring in a large majority of embryos. The organization of the vegetal cortex F-actin was also strongly disrupted, and epiboly progression was severely delayed (Fig 6B). These observations indicate the KT09 extract is causing a delay in epiboly by substantially impairing the actomyosin mechanisms in the yolk cell that drive this process.

Fig 6. Delayed epiboly progression and disruption of F-actin organization caused by KT09 extract treatment.

Fig 6

Embryos were treated with KT09 extract starting at 2hpf, while phalloidin and DAPI staining was performed at 80% epiboly (9hpf). (A-A”) A control embryo at 90% epiboly stage, with a dense marginal actin ring (white arrows). (B-B”) A representative embryo expose to KT09 extract shows epiboly retardation, and disruption of the EVL cortical F-actin, marginal actin ring and vegetal cortex F-actin. Scale bar: 100 μm.

Effect of M. bealei (KT09) extract on cell migration

After observing that the KT09 extract could delay epiboly cell movements in zebrafish embryos, we wondered whether a similar effect could be observed on mammalian cell migration. Mouse embryo fibroblast (MEF) cells were used to first investigate the effect of the KT09 effect on cell viability. The results revealed an IC50 value of 138.8 μg/mL, an IC10 of 4μg/mL and a NOEC of 2 μg/mL while no cells survived at 900 μg/mL of KT09 extract (Fig 7A and 7B).

Fig 7.

Fig 7

A. MEFs cell pictures after 48 hours of exposure to KT09 extract at different concentrations. B. Inhibition growth rate of MEFs cell exposed to KT09 extract in dose dependent manner (IC50 = 138.8 μg/mL). C. Pictures of the scratch taken at four different time points 0, 12, 18, and 22 hours after being exposed to KT09 extract. White dotted lines indicate the cell boundaries. (KT09 0.4 μg/mL inhibits 0% cell proliferation; KT09 2 μg/mL inhibits 10% cell proliferation; orange arrow: extract residue; scale bar: 200 μm). D. Graph displaying the percentage of wound recovery following KT09 extract exposure at various time points.

To investigate the impact of the KT09 extract on cell migration in vitro, the ability of MEF cells to heal a wound applied to the cell monolayer was evaluated at the concentrations, respectively 0.4 μg/mL and 2 μg/mL. Wounds of comparable width and size were made in the wells of control and treated group. The cells in the control and 0.1% DMSO wells recovered at the same rate, indicating that the DMSO solvent content in the extract had no effect on the cells’ wound healing abilities (Fig 7C). In contrast, the wounds recovered more slowly in cells exposed to KT09 extracts than in controls, with the percentage of wound area recovered in wells treated with 0.4 μg/mL and 2 μg/mL of KT09 being 93%±5% and 85%±5%, respectively, while the wound recovery rate in the control well was approximately 97% (Fig 7D). The result of the two-way ANOVA revealed that the difference in recovery between wells exposed to KT09 extract and control was statistically significant (p<0.05).

Chemical components of the M. bealei (KT09) extract

To gain some insight into the chemical compounds present in the M. bealei extract, we compared the extract to several reference alkaloids under the same HPLC-DAD conditions. The UV chromatograms at 270 nm revealed that the extract contained jatrorrhizine, isotetradine, 8-oxypalmatine, oxyberberine, 8-oxyberberubine, berberine, and palmatine (Fig 8, S2 and S3 Figs), with berberine and palmatine contributing the vast majority of alkaloids [46] in the extract as shown by their largest peak area on the chromatogram (Fig 8A)(respectively 121 ± 9 mg/g and 15.2 ± 0.2 mg/g of the total extract) [46].

Fig 8. Chemical composition of the M. bealei extract and activities of major compounds.

Fig 8

(A) HPLC chromatogram (at UV wavelength 270 nm) of the M. bealei extract is shown. The different detected compounds are indicated by arrows pointing at the corresponding peaks, with the two major peaks (peaks 3 and 4) corresponding to, respectively palmatine and berberine, while minor peaks (vertical ticks) correspond to jatrorrhizine, isotetradine, 8-oxypalmatine, oxyberberine, and 8-oxyberberrubine (B, C) Representative images of 10 hpf (B) and 24 hpf (C) zebrafish embryos exposed to M. bealei crude extract, berberine, or palmatine at the indicated concentrations.

When we tested purified berberine and palmatine at the concentrations of 50 μg/mL and 5 μg/mL, higher than the respectively 12 μg/mL and 1.5 μg/ml in the KT09 extract, no effect was observed on epiboly retardation, vascular development, or general embryogenesis (Fig 8B and 8C).

Effect of M. bealei (KT09) extract on gene expression in zebrafish embryos

To further deepen our understanding of the effects caused by the plant extracts on zebrafish development, we decided to investigate their effects on whole genome gene expression using RNA-Seq analysis. We decided to focus (first) on the earliest effect that we detected; the dumb-bell shape of the embryo observed during the epiboly process. We chose to treat the fertilized eggs with the KT09 extract at 100 μg/ml, as this was the treatment where this defect was most consistently observed, and we purified whole embryo mRNA from control and treated individuals at 8 hpf to perform transcriptomic analysis.

RNA-Seq analysis revealed the presence of 2855 differentially expressed genes (DEGs) (adjusted p-value < 0.05, fold-change > |1.5|), 1335 up-regulated and 1520 down-regulated genes (S1 Table) (GEO Series accession number GSE207770 on NCBI’s Gene Expression Omnibus [56]).Among the genes whose expression was most highly affected (S2 Table), one striking observation is the presence of many transcription factor genes that are downregulated. These genes include several hox genes involved in anterior/posterior pattern specification and embryonic skeletal system morphogenesis [57], genes of the pax family instrumental in patterning and organ development, and the nr2f5 gene coding for a nuclear receptor involved in upper jaw development [58]. Another strongly repressed gene is the wnt8b gene, which is involved in zebrafish neuron development and guidance [59, 60]. Among the most upregulated genes are myo1g, predicted to enable actin filament binding and motor activity, and dachb involved in pancreas and inner ear development [61, 62].

Gene ontology analysis was performed on the list of DEGs affected by the KT09 extract. We performed GSEA analysis, as it considers the extent to which a gene is up- or downregulated. This analysis identified many developmental processes to be affected, such as sensory and nervous system development, head development, cell differentiation, and pattern specification (S3 and S4 Tables). Main molecular functions affected were transcriptional regulation, but also receptor regulation and protein dimerization, as also identified by the biological processes of gene expression regulation and second messenger mediated signaling. Among the prominent signaling pathways affected, the most cited was the Wnt pathway, but also Shh and BMP signaling. A closer inspection using the Wikipathways database revealed that 13 genes in the canonical Wnt pathway were downregulated, while 13 genes of the noncanonical Wnt pathway were upregulated (Fig 9A and S5 Table). The wnt8b gene was among the most down-regulated genes, as well as the Wnt receptor genes fzd1 and fzd10, while wnt5b was unaffected (Fig 9A). Note that the beta catenin gene ctnnb2, a central transcription factor for canonical Wnt signaling, was up-regulated 1.68-fold.

Fig 9. Pathways affected upon treatment with M. bealei extract.

Fig 9

(A) Differentially expressed genes related to Wnt signaling upon KT09 treatment. A network was constructed based on the DEGs (p<0.05; fold-change > |1.4|). Shapes used indicate genes attributed to the canonical Wnt pathway (squares), the non-canonical pathway (triangles), both pathways (circles), or none (diamonds). The red and green ellipses highlight the genes that are specific to, respectively the non-canonical and the canonical Wnt pathway. (B) Differentially expressed genes upon KT09 treatment related to epiboly. A network was constructed based on the DEGs (p<0.05; fold-change > |1.3|). The color intensity indicates the fold-change of down-regulated (green) and up-regulated (red) genes by KT09 treatment. The lines correspond to relations of co-expression (violet), physical interaction between encoded proteins (pink), and genetic interaction (light green).

Focusing on the main defect observed in treated embryos, we collected a list of 42 genes whose mutation was shown to affect epiboly (zfin.org), among which 12 saw their expression changed by a factor of 1.5, and 19 genes displayed at least a 1.3-fold, but highly significant change in expression (Fig 9B and S5 Table). Other processes involving cellular movement were also significantly altered, such as cell migration, egg coat formation, neural crest cell migration (S3 and S4 Tables). Consistent with these observations, the actin cytoskeleton was detected as downregulated.

Several pathways were pointed out that may be involved in the defects in skeletal development that we observed, such as chondrocranium, cranial, and ceratohyal cartilage, as well as pharyngeal endoderm, BMP signaling, endochondral ossification, and collagen formation. Similarly, the alterations of movement behaviors could be related to DEGs connected to neural development and locomotion terms.

Discussion

Traditional medicinal plants are widely, and increasingly used all over the world as an alternative or a complement to mainstream treatments. Their "soft" or "natural medicine" reputation is rooted in popular knowledge accumulated over generations of traditional healers, both concerning their pharmaceutical actions and their innocuity. However, in many cases, objective assessment of both their beneficial and their toxic potential is lacking, mainly due to the enormous workload and cost that these analyses would incur. Here, we set out to use the zebrafish as a cheap and easy model to test the effects of medicinal plant extracts on vertebrate development. Focusing on the embryogenesis, this approach allows us to evaluate effects on early development, but we also rapidly assess other pathways and processes that may play a role in pathogenesis at later life stages.

Traditional practitioners prepare the most common oral drugs by decocting in water for many hours at high temperature, and a few medicinal plants are soaked in alcohol at a concentration of around 40%. Both water and alcohol were used separately for extraction of all the plants we investigated, both because of their habitual uses and because they are typical solvents for polar and nonpolar chemicals. In the study’s preliminary screening tests, aqueous extracts exhibited mostly no, or very minor activity. Therefore, we decided to restrict our study to ethanolic extracts of the relevant parts of the plants to ensure comparable extraction conditions for the different plants.

Looking at lethality and teratogenicity tests of all 12 extracts (Table 2), we observed that KT02 and KT14 caused lethality only at 72 and 96hpf, while extracts KT06, KT08, and KT19 did not cause any developmental defects at 24 and 48hpf, but did so at later stages with similar EC50 values as other extracts. One possible explanation is that the younger embryos may have been protected from the toxic or teratogenic compounds by the chorion. Future experiments, using dechorionated embryos or microinjecting the extracts into the chorion, will enable us to solve this issue.

Focusing on specific developmental defects at early stages, we selected 6 extracts to test their effects at non-lethal concentrations (LC0 = NOEC (no observed effect concentration), LC10, and LC25), that we summarize in Table 4 for easier reference. One of the earliest defects observed to some extent with all extracts was the delayed epiboly, giving rise to dumb-bell shaped yolks at 8 and 10hpf. As explained above, epiboly is the first morphogenetic movement of cells in zebrafish that depends on the dynamic regulation of cortical F-actin (filamentous actin) in the EVL [52]. Focusing on the treatment with KT09, we confirmed a significant reduction of the F-actin signal and a clear delay in the epiboly progress at 9hpf (Fig 6). These F-actin networks are essential for the circumferential constriction of the margin during late epiboly stages, and for the structural integrity of the yolk cell [52, 54, 63]. Treating embryos with the actin-depolymerizing agent cytochalasin at 50% epiboly delayed epiboly, blocked blastopore closure, and led to yolk cell lysis [54], while inhibiting signaling through the small G protein Rac1 disrupted the F-actin organization and/or delayed epiboly [55]. RNA-Seq analysis confirmed that genes whose mutation affects epiboly [52, 63] (zfin.org) had their mRNA levels at 10hpf changed at least 1.3-fold upon treatment with KT09 (Fig 9B).

Table 4. Summary of the observed biological activities with active concentration.

Extract Embryonic malformation SIVs ramification Cartilage formation Locomotion Capacity
KT02 Dumb-bell shaped yolk, Oedema, Necrosis (100 μg/mL) → death rate increased after 72hpf Defect seen at > = 40 μg/mL Weak staining of all regions (100 μg/mL) Significant increases of swimming activity in the dark (100 μg/mL)
KT11 Dumb-bell shaped yolk, Oedema, Necrosis, Curvature, Hatching delay (50 μg/mL) → death rate increased within 24hpf, and after 72hpf Defect seen at > = 20 μg/mL Weak staining of ceratobranchial and ethmoid plate (75 μg/mL) Increased swimming activity in the dark (50 μg/mL)
KT14 Dumb-bell shaped yolk, Oedema, Necrosis, Curvature, Embryos died once they hatched (100 μg/mL) →death rate increased after 48hpf Defect seen at > = 20μg/mL Shortened jaw structure (100 μg/mL) Increases of swimming activity in the dark (100 μg/mL)
KT15 Dumb-bell shaped yolk, Oedema, Necrosis, Hemorrhage, Curvature (50 μg/mL) → death rate increased after 72hpf No effect Shortened jaw and structural change (100 μg/mL) Increases of swimming activity in the dark (100 μg/mL)
KT20 Mild Dumb-bell shaped yolk, Oedema, Curvature (100 μg/mL) →death rate increased within 24hpf No effect Shortened jaw and structural change in all regions (200 μg/mL) Largest increase in swimming behavior (200 μg/mL)
KT09 Dumb-bell shaped yolk, Oedema, Necrosis, Curvature, Hatching delay (50 μg/mL), clearly developmental retardation → death rate increased within 24hpf Defect seen at > = 10 μg/mL Shortened jaw structure (75 μg/mL) Decreased activity in the dark →swimming activity not different between dark and light periods (75 μg/mL)
F–actin Cell migration RNA seq
KT09 reduced cortical F-actin in the EVL and weak actin ring, vegetal cortex F-actin disrupted →epiboly progression severely delayed (100 μg/mL) MEF cell migration inhibited→ wound recovery slowed (2 μg/mL) Gene expression and pathways modified: Wnt signaling, epiboly, cell migration, egg coat formation, neural crest cell migration… (100 μg/mL)

In this context, it is also striking that RNA-Seq analysis of the 10hpf transcriptome revealed that the Wnt pathway was most significantly affected upon KT09 treatment. Studies following single cell movements revealed that the inhibitor C59, disrupting Wnt protein maturation, causes delayed epiboly in zebrafish embryos [64]. Wnt5b was shown to be required for early cell movements by regulating Rac1, Cdc42, and finally actin filament dynamics [65], however the wnt5b gene expression was unaffected. Our results indicate that the canonical Wnt pathway, induced by Wnt5b and acting through ß-catenin, is down-regulated, while the non-canonical pathway is up-regulated upon KT09 treatment. Note also that our analysis included maternal mRNA, mainly from the yolk, thus the observed changes may be due to transcriptional effects, but also differential maturation or degradation. Exactly how these changes may affect early epiboly, or other effects that we observed, and how far they may occur upon treatment with other extracts remains to be investigated.

Another striking effect of the various plant extracts is the hatching delay observed with KT09 and KT11 treatment. Although this delay could be caused by inhibition of the proteases He1a and Cathepsin L ([66] produced by the zebrafish hatching gland, it is also noteworthy that among the most strongly downregulated genes by KT09 at 10hpf are the slc39a7 and sp63 genes (S5 Table), both shown to be required for hatching gland development [67, 68].

It is tempting to speculate that defects in cell migration during epiboly around 8 to 10hpf may be related to the observed defects in SIV formation at later stages. However, as pointed out above, the concentrations causing SIV defects are much lower than those leading to delay of epiboly. SIV formation is mainly associated with vEGF signaling at later stages, it is however interesting to see that among the genes downregulated by KT09 at 10hpf, the s1pr1 gene and the hoxd4a gene are both described to be required for SIV formation [69, 70].

At later stages (5dpf), we observed various deformities and defects in head cartilage formation, which may be caused by interference of the different extracts with various signaling pathways that are known to be involved in this complex process [50, 71]. In the case of KT09 treatment, the observed cartilage defects (weak staining, shortened chondrocranium) may be linked to the observed downregulation of Hox genes, known to control cranial cartilage patterning, however further studies would be required for this and other extracts. Similarly, the observed effects of the different extracts on locomotor behavior are probably linked to the observed perturbations in early central nervous system development.

In recent years, detection of anti-tumor activities of traditional medicinal plants attracted much attention, often based on testing the effects of extracts on proliferation, survival, or apoptosis of tumor cell lines [7274]. Here, we observed for the first-time defects in epiboly and SIV formation following treatment with several of the extracts investigated, which led us to test whether one of them, the KT09 extract would also act on mammalian cell migration. We observed a significant inhibition of cell migration of primary mouse embryonic fibroblasts, without affecting their survival or proliferation. Recently, it was shown in a small-scale, pilot chemical screening experiment that 30% of the compounds causing disruption of epiboly/gastrulation in zebrafish embryos were also able to inhibit human cancer cell motility without affecting their proliferation. One of these drugs was shown to inhibit cell invasion by metastatic human cancer cells and cancer metastasis in mouse models [75]. Thus, our results indicate that some of the extracts tested here may find a new application in preventing cancer metastasis.

Chemical alkaloid composition of the KT09 crude extract was analyzed, revealing that the extract contained jatrorrhizine, isotetradine, 8-oxypalmatine, oxyberberine, 8-oxyberberubine, berberine, and palmatine. Quantification revealed that berberine and palmatine were the major compounds (respectively 12% and 1.5% w/w) in the M. bealei (KT09) extract [46]. Berberine was previously shown to be most probably responsible for the plant’s pharmaceutical anti-fungal properties. However, preliminary findings examining the effects of berberine and palmatine on the epiboly process in zebrafish did not reveal a similar impact to that of crude extract. At 8–10 hpf, the dumb-bell shaped yolk phenomenon was not observed in embryos treated with concentrations of berberine or palmatine, even at a much higher dose than that present in the crude extract (Fig 8B and 8C). According to https://medlineplus.gov/druginfo/natural/1126.html#Safety, berberine is safe to be used at doses of 1.5 grams daily for 6 months, with possible side effects on the digestive tract probably due to its anti-bacterial action on the intestinal microflora. Similarly, palmatine has antibacterial activity, while it was also shown to be toxic for human hepatocytes and cardiomyocytes in vitro [76], however none of these activities would be predicted to cause the developmental defects investigated here. Consequently, it still remains unclear which phytochemicals account for this observed effect. Another intriguing finding was that KT09 treatment had the highest impact on the Wnt pathway, which is critical in cardiomyocyte development. Indeed, previous reports have shown that M. bealei (KT09), and specifically berberine, can have beneficial effects on heart function [7779]. For the perspective of this research, therefore, alternative applications of KT09 should be exploited and the chemical constituents responsible for its properties should be identified.

Conclusions

Taken together, our results show that the zebrafish embryotoxicity test reveals potential toxic or developmental effects caused by extracts from traditional medicinal plants (Table 4). The traditional use of the different medicinal plants investigated here range from anti-inflammatory, stomachache, and duodenum ulcers (KT14), anti-tumor (KT09, KT11, KT14, KT20), antioxidant, antimicrobial to antiviral [72, 80, 81]. A literature review of their chemical composition revealed compounds of particular interest, such as quercetin, ursolic acid, berberine and palmatine [72, 82, 83]. These substances are found in more than one plant and have been reported to exhibit activities that are associated with those in our findings [76, 8487]. Our results would advice caution concerning the toxicity of KT12, while the effects on zebrafish embryo development may suggest caution when using the extracts to treat young children or pregnant women. However, it is also obvious that further research will be required to assess the effects on human systems, the bioavailability of the compounds to the developing embryo, and the dose used for treatment. Further studies are also needed to confirm the mechanisms of toxico/pharmacological properties of these medicinal plants, as well as which components contribute to such activities. Studies using zebrafish larvae can help directing toxicological research towards specific pathways, but may also provide hints to identify new, beneficial properties that may finally lead to new applications or drugs.

Supporting information

S1 Fig. Survival curves for each experimental day upon treatment with 6 different medicinal plant extracts.

(TIF)

S2 Fig. HPLC chromatograms of M. bealei extract.

HPLC chromatograms of M. bealei extract and in-house reference compounds, including jatrorrhizine, isotetradine, 3-hydroxy-8-oxopalmatine, 8-oxypalmatine, oxyberberine, rugosinone, 8-oxyberberrubine, berberine, and palmatine.

(TIF)

S3 Fig. Extended chromatograms of M. bealei extracts.

Extended chromatograms (-6 to 16 mAu) of M. bealei extract, jatrorrhizine, isotetradine, 3-hydroxy-8-oxopalmatine, 8-oxypalmatine, oxyberberine, rugosinone, and 8-oxyberberrubine. Matched compounds (jatrorrhizine, isotetradine, 8-oxypalmatine, oxyberberine, and 8-oxyberberrubine) are marked on the chromatogram of the extract.

(TIF)

S4 Fig. Structures of the compounds detected in M. bealei extract.

(TIF)

S1 Table. Differentially expressed genes (DEGs) at 10hpf upon treatment with KT09.

(XLSX)

S2 Table. Genes most affected by KT09 treatment.

(DOCX)

S3 Table. GSEA-GO-term analysis of DEGs.

(DOCX)

S4 Table. All enrichment analyses.

ORA indicates "Over-Representation analysis" using UP- or DOWN-regulated genes, GSEA indicates ’Gen Set Enrichment Analysis", used databases were GO, KEGG, Panther, Reactome, Wikipathways, and a home-made zebrafish mutant gene-phenotype list, "description" and "size" gives the name and size of the corresponding term, "overlap" indicates the number of genes in the dataset, "enrichmentRatio" indicates the enrichment factor in the term, while pValue and FDR (False Discovery Rate) indicate the statistical significance of the enrichment, "userId" holds the list of the overlapping genes in the dataset.

(XLSX)

S5 Table. Genes whose mutation affects selected processes.

(XLSX)

Acknowledgments

We would like to thank the GIGA zebrafish platform (H. Pendeville-Samain) for taking care of and delivering the zebrafish larvae, the GIGA imaging platform for their help and support with microscopy, the GIGA genomic platform for sequencing, and the GIGA bioinformatics platform for data analysis.

Data Availability

Data relevant to this study are available from NCBI's Gene Expression Omnibus at GEO Series accession number GSE207770.

Funding Statement

This research was funded by ARES (Académie de Recherche et d'Enseignement Supérieur)(https://www.ares-ac.be/fr/), grant number PRD17: "Exploring the medical, (eco)-toxicological and socio-economic potential of natural extracts from Northern Vietnam.” M.H.T. was a fellow from ARES, G.G-L. had a fellowship from EU project MSCA_ITN PROTECTED and M.M. is a "Maître de Recherche" at FNRS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Kumar B, Vijayakumar M, Govindarajan R, Pushpangadan P. Ethnopharmacological approaches to wound healing—exploring medicinal plants of India. Journal of ethnopharmacology. 2007;114(2):103–13. Epub 2007/09/22. doi: 10.1016/j.jep.2007.08.010 . [DOI] [PubMed] [Google Scholar]
  • 2.Nguyen TH, Nguyen PD, Quetin-Leclercq J, Muller M, Ly Huong DT, Pham HT, et al. Developmental Toxicity of Clerodendrum cyrtophyllum Turcz Ethanol Extract in Zebrafish Embryo. Journal of ethnopharmacology. 2021;267:113538. Epub 2020/11/05. doi: 10.1016/j.jep.2020.113538 . [DOI] [PubMed] [Google Scholar]
  • 3.Nguyen TD, Thuong PT, Hwang IH, Hoang TK, Nguyen MK, Nguyen HA, et al. Anti-Hyperuricemic, Anti-Inflammatory and Analgesic Effects of Siegesbeckia orientalis L. Resulting from the Fraction with High Phenolic Content. BMC Complement Altern Med. 2017;17(1):191. Epub 2017/04/06. doi: 10.1186/s12906-017-1698-z ; PubMed Central PMCID: PMC5379685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Salimikia I, Bahmani M, Abbaszadeh S, Rafieian-Kopaei M, Nazer MR. Campylobacter: A Review of New Promising Remedies with Medicinal Plants and Natural Antioxidants. Mini Rev Med Chem. 2020;20(15):1462–74. Epub 2020/01/23. doi: 10.2174/1389557520666200117141641 . [DOI] [PubMed] [Google Scholar]
  • 5.Nikhade N, Telrandhe R, Ansari M. A Review of Natural Antioxidants In Medicinal Plants. International Journal of Pharmaceutics and Drug Analysis. 2019;7(2):11–5. [Google Scholar]
  • 6.Buyel JF. Plants as sources of natural and recombinant anti-cancer agents. Biotechnology advances. 2018;36(2):506–20. Epub 2018/02/07. doi: 10.1016/j.biotechadv.2018.02.002 . [DOI] [PubMed] [Google Scholar]
  • 7.Boakye YD, Agyare C, Abotsi WK, Ayande PG, Ossei PP. Anti-inflammatory activity of aqueous leaf extract of Phyllanthus muellerianus (Kuntze) Exell. and its major constituent, geraniin. Journal of ethnopharmacology. 2016;187:17–27. Epub 2016/04/23. doi: 10.1016/j.jep.2016.04.020 . [DOI] [PubMed] [Google Scholar]
  • 8.Owoyele VB, Adediji JO, Soladoye AO. Anti-inflammatory activity of aqueous leaf extract of Chromolaena odorata. Inflammopharmacology. 2005;13(5–6):479–84. Epub 2005/11/11. doi: 10.1163/156856005774649386 . [DOI] [PubMed] [Google Scholar]
  • 9.WHO Regional Office for the Western Pacific. in "Medicinal Plants in Viet Nam". WHO Regional Publications Western Pacific Series. 2009;3(ISBN-13 ‏: ‎ 978–9290611011):1–401. [Google Scholar]
  • 10.Loi DT, Dung NX. Native drugs of Vietnam: which traditional and scientific approaches? Journal of ethnopharmacology. 1991;32(1–3):51–6. doi: 10.1016/0378-8741(91)90103-k . [DOI] [PubMed] [Google Scholar]
  • 11.Ky TV. in "The Complete Collection of Traditional Pharmacology". Da Nang Publishing House. 2018. [Google Scholar]
  • 12.Duc LT. in “Vietnamese medicinal plants grown, processed and treated by physician Le Tran Duc. Dan Tri Publishing House. 2020. [Google Scholar]
  • 13.Vo VC. in "Dictionary of Medicinal Plants in Vietnam". Medicine Publisher, Ha Noi, Vietnam. 2012;1:175–6. [Google Scholar]
  • 14.Loi DT. Những cây thuốc và vị thuốc Việt Nam–Vietnamese traditional medicine and traditional medicinal plants. 1999. [Google Scholar]
  • 15.Love DR, Pichler FB, Dodd A, Copp BR, Greenwood DR. Technology for high-throughput screens: the present and future using zebrafish. Current opinion in biotechnology. 2004;15(6):564–71. doi: 10.1016/j.copbio.2004.09.004 . [DOI] [PubMed] [Google Scholar]
  • 16.MacRae CA, Peterson RT. Zebrafish as tools for drug discovery. Nat Rev Drug Discov. 2015;14(10):721–31. doi: 10.1038/nrd4627 . [DOI] [PubMed] [Google Scholar]
  • 17.Strahle U, Scholz S, Geisler R, Greiner P, Hollert H, Rastegar S, et al. Zebrafish embryos as an alternative to animal experiments—a commentary on the definition of the onset of protected life stages in animal welfare regulations. Reprod Toxicol. 2012;33(2):128–32. doi: 10.1016/j.reprotox.2011.06.121 . [DOI] [PubMed] [Google Scholar]
  • 18.Selderslaghs IW, Blust R, Witters HE. Feasibility study of the zebrafish assay as an alternative method to screen for developmental toxicity and embryotoxicity using a training set of 27 compounds. Reprod Toxicol. 2012;33(2):142–54. doi: 10.1016/j.reprotox.2011.08.003 . [DOI] [PubMed] [Google Scholar]
  • 19.Nguyen T, Nachtergael A, Mai NT, Cornet V, Duez P, Muller M, et al. Anti-inflammatory properties of the ethanol extract from Clerodendrum cyrtophyllum Turcz based on in vitro and in vivo studies. Journal of ethnopharmacology. 2020:112739. Epub 2020/03/07. doi: 10.1016/j.jep.2020.112739 . [DOI] [PubMed] [Google Scholar]
  • 20.Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. Stages of embryonic development of the zebrafish. Dev Dyn. 1995;203(3):253–310. doi: 10.1002/aja.1002030302 . [DOI] [PubMed] [Google Scholar]
  • 21.Howe K, Clark MD, Torroja CF, Torrance J, Berthelot C, Muffato M, et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature. 2013;496(7446):498–503. Epub 2013/04/19. doi: 10.1038/nature12111 ; PubMed Central PMCID: PMC3703927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Rubinstein AL. Zebrafish assays for drug toxicity screening. Expert Opin Drug Metab Toxicol. 2006;2(2):231–40. Epub 2006/07/27. doi: 10.1517/17425255.2.2.231 . [DOI] [PubMed] [Google Scholar]
  • 23.Ducharme NA, Reif DM, Gustafsson JA, Bondesson M. Comparison of toxicity values across zebrafish early life stages and mammalian studies: Implications for chemical testing. Reprod Toxicol. 2015;55:3–10. doi: 10.1016/j.reprotox.2014.09.005 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Peterson RT, Macrae CA. Systematic approaches to toxicology in the zebrafish. Annu Rev Pharmacol Toxicol. 2012;52:433–53. Epub 2011/10/25. doi: 10.1146/annurev-pharmtox-010611-134751 . [DOI] [PubMed] [Google Scholar]
  • 25.Voncken A, Piot A, Stern O, Marée R, Peers B, Wehenkel L, et al. Zebrafish as model in toxicology/pharmacology. Biomedica 2010, Aachen, Germany 2010. 2010. [Google Scholar]
  • 26.Scholz S, Fischer S, Gundel U, Kuster E, Luckenbach T, Voelker D. The zebrafish embryo model in environmental risk assessment—applications beyond acute toxicity testing. Environ Sci Pollut Res Int. 2008;15(5):394–404. Epub 2008/06/26. doi: 10.1007/s11356-008-0018-z . [DOI] [PubMed] [Google Scholar]
  • 27.OECD. Guidance document on the validation and international acceptance of new or updated test methods for hazard assessment. OECD SERIES ON TESTING AND ASSESSMENT. 2005;34. [Google Scholar]
  • 28.Lawson ND, Weinstein BM. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol. 2002;248(2):307–18. Epub 2002/08/09. doi: 10.1006/dbio.2002.0711 . [DOI] [PubMed] [Google Scholar]
  • 29.Westerfield M. THE ZEBRAFISH BOOK, 5th Edition; A guide for the laboratory use of zebrafish (Danio rerio), Eugene, University of Oregon Press. 2007. [Google Scholar]
  • 30.Lammer E, Carr GJ, Wendler K, Rawlings JM, Belanger SE, Braunbeck T. Is the fish embryo toxicity test (FET) with the zebrafish (Danio rerio) a potential alternative for the fish acute toxicity test? Comp Biochem Physiol C Toxicol Pharmacol. 2009;149(2):196–209. Epub 2008/12/20. doi: 10.1016/j.cbpc.2008.11.006 . [DOI] [PubMed] [Google Scholar]
  • 31.Jeanray N, Marée R, Pruvot B, Stern O, Geurts P, Wehenkel L, et al. Phenotype classification of zebrafish embryos by supervised learning. PLoS One. 2015;10(1):e0116989. e0116989. doi: 10.1371/journal.pone.0116989 ; PubMed Central PMCID: PMC4289190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Segner H. Zebrafish (Danio rerio) as a model organism for investigating endocrine disruption. Comp Biochem Physiol C Toxicol Pharmacol. 2009;149(2):187–95. Epub 2008/10/29. doi: 10.1016/j.cbpc.2008.10.099 . [DOI] [PubMed] [Google Scholar]
  • 33.Nagel R. DarT: The embryo test with the zebrafish Danio rerio—a general model in ecotoxicology and toxicology. Altex-Altern Tierexp. 2002;19:38–48. ISI:000177300300008. [PubMed] [Google Scholar]
  • 34.Alqahtani S, Nasr FA, Noman OM, Farooq M, Alhawassi T, Qamar W, et al. Cytotoxic Evaluation and Anti-Angiogenic Effects of Two Furano-Sesquiterpenoids from Commiphora myrrh Resin. Molecules. 2020;25(6). Epub 2020/03/19. doi: 10.3390/molecules25061318 ; PubMed Central PMCID: PMC7144466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Serbedzija GN, Flynn E, Willett CE. Zebrafish angiogenesis: a new model for drug screening. Angiogenesis. 1999;3(4):353–9. Epub 2003/10/01. doi: 10.1023/a:1026598300052 . [DOI] [PubMed] [Google Scholar]
  • 36.Raghunath M, Sy Wong Y, Farooq M, Ge R. Pharmacologically induced angiogenesis in transgenic zebrafish. Biochem Biophys Res Commun. 2009;378(4):766–71. Epub 2008/12/11. S0006-291X(08)02332-2 [pii]. doi: 10.1016/j.bbrc.2008.11.127 . [DOI] [PubMed] [Google Scholar]
  • 37.Aceto J, Nourizadeh-Lillabadi R, Bradamante S, Maier J, Alestrom P, Van Loon J, et al. Effects of microgravity simulation on zebrafish transcriptomes and bone physiology; exposure starting at 5 days post-fertilization. npj Microgravity. 2016;2:16010. Epub 7 April 2016. doi: 10.1038/npjmgrav.2016.10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Walker MB, Kimmel CB. A two-color acid-free cartilage and bone stain for zebrafish larvae. Biotech Histochem. 2007;82(1):23–8. Epub 2007/05/19. 778819433 [pii]. doi: 10.1080/10520290701333558 . [DOI] [PubMed] [Google Scholar]
  • 39.Dalcq J, Pasque V, Ghaye A, Larbuisson A, Motte P, Martial JA, et al. Runx3, Egr1 and Sox9b form a regulatory cascade required to modulate BMP-signaling during cranial cartilage development in zebrafish. PLoS One. 2012;7(11):e50140. Epub 2012/12/05. doi: 10.1371/journal.pone.0050140 ; PubMed Central PMCID: PMC3507947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Hintermann E, Bilban M, Sharabi A, Quaranta V. Inhibitory role of alpha 6 beta 4-associated erbB-2 and phosphoinositide 3-kinase in keratinocyte haptotactic migration dependent on alpha 3 beta 1 integrin. J Cell Biol. 2001;153(3):465–78. Epub 2001/05/02. doi: 10.1083/jcb.153.3.465 ; PubMed Central PMCID: PMC2190561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Koivisto L, Jiang G, Hakkinen L, Chan B, Larjava H. HaCaT keratinocyte migration is dependent on epidermal growth factor receptor signaling and glycogen synthase kinase-3alpha. Exp Cell Res. 2006;312(15):2791–805. Epub 2006/06/30. doi: 10.1016/j.yexcr.2006.05.009 . [DOI] [PubMed] [Google Scholar]
  • 42.Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, et al. The nf-core framework for community-curated bioinformatics pipelines. Nat Biotechnol. 2020;38(3):276–8. Epub 2020/02/15. doi: 10.1038/s41587-020-0439-x . [DOI] [PubMed] [Google Scholar]
  • 43.Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. Epub 2014/12/18. doi: 10.1186/s13059-014-0550-8 ; PubMed Central PMCID: PMC4302049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Kanehisa M, Sato Y, Kawashima M. KEGG mapping tools for uncovering hidden features in biological data. Protein Sci. 2022;31(1):47–53. Epub 2021/08/24. doi: 10.1002/pro.4172 ; PubMed Central PMCID: PMC8740838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30. Epub 1999/12/11. doi: 10.1093/nar/28.1.27 ; PubMed Central PMCID: PMC102409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Tran HM, Le DH, Nguyen VT, Vu TX, Thanh NTK, Giang DH, et al. Penicillium digitatum as a Model Fungus for Detecting Antifungal Activity of Botanicals: An Evaluation on Vietnamese Medicinal Plant Extracts. J Fungi (Basel). 2022;8(9). Epub 2022/09/23. doi: 10.3390/jof8090956 ; PubMed Central PMCID: PMC9502062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.R Core Team. R: A language and environment for statistical computing (4.0.2). R Foundation for Statistical Computing, Vienna, Austria. http://wwwr-projectorg/indexhtml (accessed 9 March 2023). 2020. [Google Scholar]
  • 48.Lenth RV. Least-Squares Means: The R Package lsmeans. Journal of Statistical Software. 2016;69(1):1–33. doi: 10.18637/jss.v069.i01 [DOI] [Google Scholar]
  • 49.OECD. Test No. 236: Fish Embryo Acute Toxicity (FET) Test. OECD Guidelines for the Testing of Chemicals, Section 2, OECD Publishing. 2013; doi: 10.1787/9789264203709-en [DOI] [Google Scholar]
  • 50.Fabik J, Psutkova V, Machon O. The Mandibular and Hyoid Arches-From Molecular Patterning to Shaping Bone and Cartilage. International journal of molecular sciences. 2021;22(14). Epub 2021/07/25. doi: 10.3390/ijms22147529 ; PubMed Central PMCID: PMC8303155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Lison L. Alcian blue 8 G with chlorantine fast red 5 B.A technic for selective staining of mycopolysaccharides. Stain Technol. 1954;29(3):131–8. Epub 1954/05/01. doi: 10.3109/10520295409115457 . [DOI] [PubMed] [Google Scholar]
  • 52.Lepage SE, Bruce AE. Zebrafish epiboly: mechanics and mechanisms. Int J Dev Biol. 2010;54(8–9):1213–28. Epub 2010/08/17. doi: 10.1387/ijdb.093028sl . [DOI] [PubMed] [Google Scholar]
  • 53.Apodaca G. Endocytic traffic in polarized epithelial cells: role of the actin and microtubule cytoskeleton. Traffic. 2001;2(3):149–59. Epub 2001/03/22. doi: 10.1034/j.1600-0854.2001.020301.x . [DOI] [PubMed] [Google Scholar]
  • 54.Cheng JC, Miller AL, Webb SE. Organization and function of microfilaments during late epiboly in zebrafish embryos. Dev Dyn. 2004;231(2):313–23. Epub 2004/09/15. doi: 10.1002/dvdy.20144 . [DOI] [PubMed] [Google Scholar]
  • 55.Li YL, Shao M, Shi DL. Rac1 signalling coordinates epiboly movement by differential regulation of actin cytoskeleton in zebrafish. Biochem Biophys Res Commun. 2017;490(3):1059–65. Epub 2017/07/03. doi: 10.1016/j.bbrc.2017.06.165 . [DOI] [PubMed] [Google Scholar]
  • 56.Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–10. Epub 2001/12/26. doi: 10.1093/nar/30.1.207 ; PubMed Central PMCID: PMC99122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Yamada K, Maeno A, Araki S, Kikuchi M, Suzuki M, Ishizaka M, et al. An atlas of seven zebrafish hox cluster mutants provides insights into sub/neofunctionalization of vertebrate Hox clusters. Development. 2021;148(11). Epub 2021/06/08. doi: 10.1242/dev.198325 . [DOI] [PubMed] [Google Scholar]
  • 58.Barske L, Rataud P, Behizad K, Del Rio L, Cox SG, Crump JG. Essential Role of Nr2f Nuclear Receptors in Patterning the Vertebrate Upper Jaw. Dev Cell. 2018;44(3):337–47 e5. Epub 2018/01/24. doi: 10.1016/j.devcel.2017.12.022 ; PubMed Central PMCID: PMC5801120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Lee JE, Wu SF, Goering LM, Dorsky RI. Canonical Wnt signaling through Lef1 is required for hypothalamic neurogenesis. Development. 2006;133(22):4451–61. Epub 2006/10/20. doi: 10.1242/dev.02613 . [DOI] [PubMed] [Google Scholar]
  • 60.Hofmeister W, Key B. Frizzled-3a and Wnt-8b genetically interact during forebrain commissural formation in embryonic zebrafish. Brain Res. 2013;1506:25–34. Epub 2013/02/27. doi: 10.1016/j.brainres.2013.02.028 . [DOI] [PubMed] [Google Scholar]
  • 61.Yang L, Webb SE, Jin N, Lee HM, Chan TF, Xu G, et al. Investigating the role of dachshund b in the development of the pancreatic islet in zebrafish. J Diabetes Investig. 2021;12(5):710–27. Epub 2021/01/16. doi: 10.1111/jdi.13503 ; PubMed Central PMCID: PMC8089008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Kalousova A, Mavropoulos A, Adams BA, Nekrep N, Li Z, Krauss S, et al. Dachshund homologues play a conserved role in islet cell development. Dev Biol. 2010;348(2):143–52. Epub 2010/09/28. doi: 10.1016/j.ydbio.2010.09.007 ; PubMed Central PMCID: PMC2997432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Lee SJ. Dynamic regulation of the microtubule and actin cytoskeleton in zebrafish epiboly. Biochem Biophys Res Commun. 2014;452(1):1–7. Epub 2014/08/15. doi: 10.1016/j.bbrc.2014.08.005 . [DOI] [PubMed] [Google Scholar]
  • 64.Bhattacharya D, Zhong J, Tavakoli S, Kabla A, Matsudaira P. Strain maps characterize the symmetry of convergence and extension patterns during zebrafish gastrulation. Scientific reports. 2021;11(1):19357. Epub 2021/10/01. doi: 10.1038/s41598-021-98233-z ; PubMed Central PMCID: PMC8481280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Hung IC, Chen TM, Lin JP, Tai YL, Shen TL, Lee SJ. Wnt5b integrates Fak1a to mediate gastrulation cell movements via Rac1 and Cdc42. Open Biol. 2020;10(2):190273. Epub 2020/02/26. doi: 10.1098/rsob.190273 ; PubMed Central PMCID: PMC7058935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Muraina IA, Maret W, Bury NR, Hogstrand C. Hatching gland development and hatching in zebrafish embryos: A role for zinc and its transporters Zip10 and Znt1a. Biochem Biophys Res Commun. 2020;528(4):698–705. Epub 2020/06/11. doi: 10.1016/j.bbrc.2020.05.131 . [DOI] [PubMed] [Google Scholar]
  • 67.Yan G, Zhang Y, Yu J, Yu Y, Zhang F, Zhang Z, et al. Slc39a7/zip7 plays a critical role in development and zinc homeostasis in zebrafish. PLoS One. 2012;7(8):e42939. Epub 2012/08/23. doi: 10.1371/journal.pone.0042939 ; PubMed Central PMCID: PMC3418240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Trikic MZ, Monk P, Roehl H, Partridge LJ. Regulation of zebrafish hatching by tetraspanin cd63. PLoS One. 2011;6(5):e19683. Epub 2011/06/01. doi: 10.1371/journal.pone.0019683 ; PubMed Central PMCID: PMC3098263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Ben Shoham A, Malkinson G, Krief S, Shwartz Y, Ely Y, Ferrara N, et al. S1P1 inhibits sprouting angiogenesis during vascular development. Development. 2012;139(20):3859–69. Epub 2012/09/07. doi: 10.1242/dev.078550 . [DOI] [PubMed] [Google Scholar]
  • 70.Amali AA, Sie L, Winkler C, Featherstone M. Zebrafish hoxd4a acts upstream of meis1.1 to direct vasculogenesis, angiogenesis and hematopoiesis. PLoS One. 2013;8(3):e58857. Epub 2013/04/05. doi: 10.1371/journal.pone.0058857 ; PubMed Central PMCID: PMC3598951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Paudel S, Gjorcheska S, Bump P, Barske L. Patterning of cartilaginous condensations in the developing facial skeleton. Dev Biol. 2022. Epub 2022/04/01. doi: 10.1016/j.ydbio.2022.03.010 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Pan X, Hou X, Zhang F, Tang P, Wan W, Su Z, et al. Gnetum montanum extract induces apoptosis by inhibiting the activation of AKT in SW480 human colon cancer cells. Pharm Biol. 2022;60(1):915–30. Epub 2022/05/20. doi: 10.1080/13880209.2022.2063340 ; PubMed Central PMCID: PMC9122364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Hu W, Yu L, Wang MH. Antioxidant and antiproliferative properties of water extract from Mahonia bealei (Fort.) Carr. leaves. Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association. 2011;49(4):799–806. Epub 2010/12/07. doi: 10.1016/j.fct.2010.12.001 . [DOI] [PubMed] [Google Scholar]
  • 74.Badavenkatappa SG, Peraman R. In vitro antitubercular, anticancer activities and IL-10 expression in HCT-116 cells of Tinospora sinensis (Lour.) Merr. leaves extract. Nat Prod Res. 2021;35(22):4669–74. Epub 2019/12/25. doi: 10.1080/14786419.2019.1705814 . [DOI] [PubMed] [Google Scholar]
  • 75.Nakayama J, Tan L, Li Y, Goh BC, Wang S, Makinoshima H, et al. A zebrafish embryo screen utilizing gastrulation identifies the HTR2C inhibitor pizotifen as a suppressor of EMT-mediated metastasis. eLife. 2021;10. Epub 2021/12/18. doi: 10.7554/eLife.70151 ; PubMed Central PMCID: PMC8824480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Long J, Song J, Zhong L, Liao Y, Liu L, Li X. Palmatine: A review of its pharmacology, toxicity and pharmacokinetics. Biochimie. 2019;162:176–84. Epub 2019/05/06. doi: 10.1016/j.biochi.2019.04.008 . [DOI] [PubMed] [Google Scholar]
  • 77.Cai Y, Xin Q, Lu J, Miao Y, Lin Q, Cong W, et al. A New Therapeutic Candidate for Cardiovascular Diseases: Berberine. Frontiers in pharmacology. 2021;12:631100. Epub 2021/04/06. doi: 10.3389/fphar.2021.631100 ; PubMed Central PMCID: PMC8010184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Feng X, Sureda A, Jafari S, Memariani Z, Tewari D, Annunziata G, et al. Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. Theranostics. 2019;9(7):1923–51. Epub 2019/05/01. doi: 10.7150/thno.30787 ; PubMed Central PMCID: PMC6485276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Zhao JV, Yeung WF, Chan YH, Vackova D, Leung JYY, Ip DKM, et al. Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial. Nutrients. 2021;13(8). Epub 2021/08/28. doi: 10.3390/nu13082550 ; PubMed Central PMCID: PMC8401658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.He JM, Mu Q. The medicinal uses of the genus Mahonia in traditional Chinese medicine: An ethnopharmacological, phytochemical and pharmacological review. Journal of ethnopharmacology. 2015;175:668–83. Epub 2015/09/22. doi: 10.1016/j.jep.2015.09.013 . [DOI] [PubMed] [Google Scholar]
  • 81.Anh NH, Park S, Trang DT, Yen DTH, Tai BH, Yen PH, et al. Genus mallotus (euphorbiaceae): a review on traditional medicinal use, phytochemistry and biological activities. Vietnam J Sci Technol. 2022;60(2):141–74. doi: 10.15625/2525-2518/16634 [DOI] [Google Scholar]
  • 82.Hedge S, Jayaraj M. A Review of the Medicinal Properties, Phytochemical and Biological Active Compounds of Tinospora sinensis (Lour.) Merr. Journal of Biologically Active Products from Nature. 2016;6(2):84–94. doi: 10.1080/22311866.2016.1185968 [DOI] [Google Scholar]
  • 83.Wu L, Wang G, Shen T, Quiang Q, Xue Q, Chen MH, et al. Chemical Constituents of Leaves of Mahonia bealei. Chemistry of Natural Compounds 2018;54(1):210–2. doi: 10.1007/s10600-018-2302-6 [DOI] [Google Scholar]
  • 84.Ahmed T, Gilani AU, Abdollahi M, Daglia M, Nabavi SF, Nabavi SM. Berberine and neurodegeneration: A review of literature. Pharmacol Rep. 2015;67(5):970–9. Epub 2015/09/24. doi: 10.1016/j.pharep.2015.03.002 . [DOI] [PubMed] [Google Scholar]
  • 85.Mahlo SM, Eloff JN. Acetone leaf extracts of Breonadia salicina (Rubiaceae) and ursolic acid protect oranges against infection by Penicillium species. South African Journal of Botany. 2014;93:48–53. doi: 10.1016/j.sajb.2014.03.003 [DOI] [Google Scholar]
  • 86.Vollekova A, Kost’alova D, Kettmann V, Toth J. Antifungal activity of Mahonia aquifolium extract and its major protoberberine alkaloids. Phytother Res. 2003;17(7):834–7. Epub 2003/08/14. doi: 10.1002/ptr.1256 . [DOI] [PubMed] [Google Scholar]
  • 87.Zhang JL, Laurence Souders C 2nd, Denslow ND, Martyniuk CJ. Quercetin, a natural product supplement, impairs mitochondrial bioenergetics and locomotor behavior in larval zebrafish (Danio rerio). Toxicol Appl Pharmacol. 2017;327:30–8. Epub 2017/04/30. doi: 10.1016/j.taap.2017.04.024 . [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Michael Klymkowsky

17 Aug 2023

PONE-D-23-05393Testing biological actions of medicinal plants from northern Vietnam on zebrafish embryos and larvae: developmental, behavioral, and putative therapeutical effects.PLOS ONE

Dear Dr. Muller,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Both reviewers' have requested a number of clarifications and revisions, please address their comments point by point.  A completely agree with reviewer #1 that speculation about conclusions on the impacts of various compounts on human pregnancy are inappropriate and should be removed until relevant mammalian studies have been carried out.  

Please submit your revised manuscript by Sep 22 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Michael Klymkowsky, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure: 

This research was funded by ARES (Académie de Recherche et d'Enseignement Supérieur)(https://www.ares-ac.be/fr/), grant number PRD17: "Exploring the medical, (eco)-toxicological and socio-economic potential of natural extracts from Northern Vietnam.” M.H.T. was a fellow from ARES, G.G-L. had a fellowship from EU project MSCA_ITN PROTECTED and M.M. is a "Maître de Recherche" at FNRS.

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

This research was funded by ARES (Académie de Recherche et d'Enseignement Supérieur), grant number PRD17: "Exploring the medical, (eco)-toxicological and socio-economic potential of natural extracts from Northern Vietnam.” M.H.T. was a fellow from ARES, G.G-L. had a fellowship from EU project MSCA_ITN PROTECTED and M.M. is a "Maître de Recherche" at FNRS.

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

This research was funded by ARES (Académie de Recherche et d'Enseignement Supérieur)(https://www.ares-ac.be/fr/), grant number PRD17: "Exploring the medical, (eco)-toxicological and socio-economic potential of natural extracts from Northern Vietnam.” M.H.T. was a fellow from ARES, G.G-L. had a fellowship from EU project MSCA_ITN PROTECTED and M.M. is a "Maître de Recherche" at FNRS.

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

5. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I found this paper interesting and the study design thorough. I have some concerns, that upon addressing, would improve this manuscript for publication

Introduction:

I disagree with the phrase ‘not considered as an animal’ (line 79). Zebrafish larvae are definitely still animals, however it is a larval stage organism and therefore not a protected species.

Methods:

Were any of the researchers blinded to the treatment groups when screening for phenotypes? Please state.

In the cell scratch assay why was DMSO not dosed at 0.5% like in the fish assays?

Did you deyolk the embryos for the RNA extraction? If yes, please state. If no, please consider the maternal RNA present in the yolk sac that influences development.

Data and analysis section states that experiments performed 3 times- please specify if this was technical replicates, or biological replicates – ie 3 separate clutches of eggs and in which case.

Discussion:

I think the discussion reads, in places, as more of a summary of results rather than a discussion of the findings, and the implications for the research field. I therefore think this manuscript would benefit from a summary table of all the effects observed by the drugs, collating the results of each assay. I suggest re-writing the discussion to limit the reiteration of the results, and to address the following questions:

Fig 8 reveals that the two main chemical components are not influencing the gross morphological phenotype. Can you discuss this further, and explain why you might anticipate these results?

The authors mention KT11 might have two different death causing processes, can you hypothesise why/what these might be in relation to the development of the zebrafish? Do you have plans to look at RNA at different time points to elucidate this? Why might it be important?

I am also concerned about the sweeping assumption that the outcomes of this study should be considered when treating pregnant women with these compounds. I don’t think that this is addressed in this study to any extent to make these claims, ie there are no human specific studies, no information about crossing the placenta, whether a prescribed therapeutic dose would reach the same toxic levels. I think making this assumption is sensationalist at this point, and therefore further research is required to base these claims. Perhaps there is more literature that can be discussed in this capacity here?

Figures:

Please add gridlines to Table 2. Can you also include the number data from Supplementary Table 1 here somehow, and include the numbers from the control groups. This will support your argument that these phenotypes are more prevalent in the treated groups, and are not standard developmental issues that are common such as cardiac oedema and spinal curvature.

Figure 3, please state the P values for each bar, what is the significance (*) determined by? What groups are being compare and by what statistical test?

Figure 4F is missing KT15 annotation

Add ‘light’ and ‘dark’ labels to graphs in Figure 5 for increased clarity.

Figure 6 – add control and KT09 labels to A and B

Fig 7B – X axis title is obscuring the labels. 7C – please define the cell boundary.

No lines visible on Figure 9

Reviewer #2: The manuscript “TESTING BIOLOGICAL ACTIONS OF MEDICINAL PLANTS FROM NORTHERN VIETNAM ON ZEBRAFISH EMBRYOS AND LARVAE: DEVELOPMENTAL, BEHAVIORAL, AND PUTATIVE THERAPEUTICAL EFFECTS.” aimed to evaluate the biological effect of plants used as Vietnamese traditional medicine on parameters of embryo development, in order to assess the possible toxic effects.

First of all, I would like to compliment the authors for the effort in investigating the toxic potential of plant extracts, which could represent a serious threat to humans. The analysis of biological potential and cellular effects of plant extracts is essential to comprehend and assure the use of these plants.

Overall, the context of the study was well introduced, and the results and discussion are well presented. However. This reviewer recommends language revision, especially on ‘Material and methods’ section. .

SPECIFIC COMMENTS:

Main text:

Standardize the units of time measurement (hours post-fertilization or days post-fertilization).

Line 460-461 - Rewrite the sentence for better understanding.

Describe with better clarity the results of visual behavior.

Line 550 – 551 - Rewrite the sentence for better understanding.

Very short conclusion. I suggest rewriting it to provide significant insights regarding the findings.

Figures

Figure 4 F – The identification of the group is missing.

Figure 5 – Standardize the colors of each extract tested.

Figure 8 – Rewrite the caption for better understanding.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Siobhan Crilly

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Nov 7;18(11):e0294048. doi: 10.1371/journal.pone.0294048.r002

Author response to Decision Letter 0


11 Sep 2023

Reviewer #1: I found this paper interesting and the study design thorough. I have some concerns, that upon addressing, would improve this manuscript for publication.

Introduction:

I disagree with the phrase ‘not considered as an animal’ (line 79). Zebrafish larvae are definitely still animals, however it is a larval stage organism and therefore not a protected species.

We agree that this was an overstatement and changed the text: "the zebrafish embryo up to the free-feeding stage at 5 days post fertilization is generally considered as larval stage; hence it can be used without raising ethical issues." (line 80 in the mark-up version).

Methods:

Were any of the researchers blinded to the treatment groups when screening for phenotypes? Please state.

Strictly speaking, the researchers were not blinded to the treatment groups, however "each treatment group was analyzed without preconception, especially regarding the specific defect observed." Our hope was indeed to not see too many defects.

We added additional explanation in the new manuscript (line 161-163)

In the cell scratch assay why was DMSO not dosed at 0.5% like in the fish assays?

It is known that zebrafish larvae will not suffer from 0.5% DMSO, which is actually what we also see, as we always compare treated and non-treated. We also wanted to be able to at least test higher concentrations of the extracts. For the scratch assay, lower concentrations were used, so we preferred to lower the DMSO concentration here.

Did you deyolk the embryos for the RNA extraction? If yes, please state. If no, please consider the maternal RNA present in the yolk sac that influences development.

Thanks for this question: indeed, we were interested in the differential mRNA pool upon treatment, thus we included the yolk. We mention this now in the Mat. and Meth. section and in the discussion. It does not affect our main conclusions.

"We chose to use whole larvae, including the yolk, as we intended to determine the entire RNA pool for evaluation of transcription, but also maturation and degradation." (lines 262-263).

"Note also that our analysis included maternal mRNA, mainly from the yolk, thus the observed changes may be due to transcriptional effects, but also differential maturation or degradation." (lines 805-807).

Data and analysis section states that experiments performed 3 times- please specify if this was technical replicates, or biological replicates – ie 3 separate clutches of eggs and in which case.

Thanks for the comment. It was always biological replicates: All experiments were performed at least three times, mostly on different dates but always on different clutches from different parents (lines 311-313).

Discussion:

I think the discussion reads, in places, as more of a summary of results rather than a discussion of the findings, and the implications for the research field. I therefore think this manuscript would benefit from a summary table of all the effects observed by the drugs, collating the results of each assay. I suggest re-writing the discussion to limit the reiteration of the results, and to address the following questions:

We actually really tried to avoid reiteration in the discussion, we now tried to do even better, and we include a summary table as suggested (Table 4, line 658). Thanks for that suggestion. However, consider that sometimes repetition is required to integrate a specific discussion point.

Specifically, we moved the lethality and teratogenicity discussion of all 12 extracts to the "Results" section (lines 364-370), leaving only the proposal that the chorion may protect younger embryos in the discussion (lines 746-751). We also shortened the epiboly discussion (lines 661-667), as that was indeed redundant to the text in the "Results"

Fig 8 reveals that the two main chemical components are not influencing the gross morphological phenotype. Can you discuss this further, and explain why you might anticipate these results?

Thanks for the question. We added text to the discussion, which may lead to anticipate our results, however we preferred to verify, and it is what we found.

"According to https://medlineplus.gov/druginfo/natural/1126.html#Safety, berberine is safe to be used at doses of 1.5 grams daily for 6 months, with possible side effects on the digestive tract probably due to its anti-bacterial action on the intestinal microflora. Similarly, palmatine has antibacterial activity, while it was also shown to be toxic for human hepatocytes and cardiomyocytes in vitro [78], however none of these activities would be predicted to cause the developmental defects investigated here." (lines 909-914)

The authors mention KT11 might have two different death causing processes, can you hypothesize why/what these might be in relation to the development of the zebrafish? Do you have plans to look at RNA at different time points to elucidate this? Why might it be important?

Thanks for the comment. Now the sentences were changed to " The survival rate of embryos was reduced at 24hpf, constant until 72hpf, and reduced again at 96hpf (S1 Fig), implying that this extract causes death at an early stage (before 24hpf) and again later, possibly due to the hatching delay. RNA-Seq analysis at different time points would help to understand the mechanisms involved." (lines 435-438)

I am also concerned about the sweeping assumption that the outcomes of this study should be considered when treating pregnant women with these compounds. I don’t think that this is addressed in this study to any extent to make these claims, ie there are no human specific studies, no information about crossing the placenta, whether a prescribed therapeutic dose would reach the same toxic levels. I think making this assumption is sensationalist at this point, and therefore further research is required to base these claims. Perhaps there is more literature that can be discussed in this capacity here?

Indeed, we probably insisted too heavily on this assumption, although it is a reason to use zebrafish larval development as a test. We now adress this point specifically in the discussion. Note that for example the use of berberine, present in many extracts, is not recommended for children and pregnant women, according to:

(https://medlineplus.gov/druginfo/natural/1126.html#Safety).

" Our results would advice caution concerning the toxicity of KT12, while the effects on zebrafish embryo development may suggest caution when using the extracts to treat young children or pregnant women. However, it is also obvious that further research will be required to assess the effects on human systems, the bioavailability of the compounds to the developing embryo, and the dose used for treatment. Further studies are also needed to confirm the mechanisms of toxico/pharmacological properties of these medicinal plants, as well as which components contribute to such activities. Studies using zebrafish larvae can help directing toxicological research towards specific pathways, but may also provide hints to identify new, beneficial properties that may finally lead to new applications or drugs." (lines 987-995)

We actually think that a lengthy discussion of this issue would be out of scope for this manuscript.

Figures:

Please add gridlines to Table 2. Can you also include the number data from Supplementary Table 1 here somehow, and include the numbers from the control groups. This will support your argument that these phenotypes are more prevalent in the treated groups, and are not standard developmental issues that are common such as cardiac oedema and spinal curvature.

Thanks for this suggestion. We now integrated former table S1 into the text, as Table 3, as this seemed the most feasible option. In addition, we added a column for controls to this table.

Figure 3, please state the P values for each bar, what is the significance (*) determined by? What groups are being compare and by what statistical test?

Comparison is always against controls (untreated). The statistical tests used are now indicated in the legends of Figures (lines 478-479 for Fig 3 and lines 536-537 for Fig 4)

Figure 4F is missing KT15 annotation

Sorry for the mistake. We addressed it.

Add ‘light’ and ‘dark’ labels to graphs in Figure 5 for increased clarity.

Thank you for your suggestion. We made the changes.

Figure 6 – add control and KT09 labels to A and B

Thank you for your comment. The labels were already added.

Fig 7B – X axis title is obscuring the labels. 7C – please define the cell boundary.

We are sorry, but we don’t get the point for Fig 7B. All labels are visible on all versions. For Fig 7C, we added white dotted lines to indicate the cell boundary in the shown examples.

No lines visible on Figure 9

The lines were indeed not very visible. We hope that it is better now, while we also try not to make it too confusing.

Reviewer #2: The manuscript “TESTING BIOLOGICAL ACTIONS OF MEDICINAL PLANTS FROM NORTHERN VIETNAM ON ZEBRAFISH EMBRYOS AND LARVAE: DEVELOPMENTAL, BEHAVIORAL, AND PUTATIVE THERAPEUTICAL EFFECTS.” aimed to evaluate the biological effect of plants used as Vietnamese traditional medicine on parameters of embryo development, in order to assess the possible toxic effects.

First of all, I would like to compliment the authors for the effort in investigating the toxic potential of plant extracts, which could represent a serious threat to humans. The analysis of biological potential and cellular effects of plant extracts is essential to comprehend and assure the use of these plants. Overall, the context of the study was well introduced, and the results and discussion are well presented. However, this reviewer recommends language revision, especially on ‘Material and methods’ section.

Thanks for the positive evaluation. The language was reassessed thoroughly

SPECIFIC COMMENTS

Main text:

Standardize the units of time measurement (hours post-fertilization or days post-fertilization).

We agree, we switched to hpf in the entire manuscript.

Line 460-461 - Rewrite the sentence for better understanding. Describe with better clarity the results of visual behavior.

We admit that this was somewhat misleading, by mentioning the control larvae, it is actually the case for almost all larvae. "In this type of test, it is known that zebrafish larvae are much more active in the dark, thus we observed a significantly increased time spent active, distance travelled and swimming speed during the dark phases for most of the conditions (lines 543-545)

Line 550 – 551 - Rewrite the sentence for better understanding.

This was indeed misleading. We now changed it to "When we tested purified berberine and palmatine at the concentrations of 50 µg/mL and 5 µg/mL, higher than the respectively 12 µg/mL and 1.5 µg/ml in the KT09 extract, no effect was observed on epiboly retardation, vascular development, or general embryogenesis (Fig 8B and 8C)." (lines 641-643)

Very short conclusion. I suggest rewriting it to provide significant insights regarding the findings.

Thank you for your comment. The conclusion now has been changed and a summary table (Table 4) was added.

Figures

Figure 4 F – The identification of the group is missing.

Sorry for this. It was added.

Figure 5 – Standardize the colors of each extract tested.

Thank you for the comment. The colors are now exactly matched for each extract.

Figure 8 – Rewrite the caption for better understanding.

There was a mistake in the B and C explanation. We hope the caption is now clearer " (A) HPLC chromatogram (at UV wavelength 270 nm) of the M. bealei extract is shown. The different detected compounds are indicated by arrows pointing at the corresponding peaks, with the two major peaks (peaks 3 and 4) corresponding to, respectively palmatine and berberine, while minor peaks (vertical ticks) correspond to jatrorrhizine, isotetradine, , 8-oxypalmatine, oxyberberine, and 8-oxyberberrubine (B, C) Representative images of 10 hpf (B) and 24 hpf (C) zebrafish embryos exposed to M. bealei crude extract, berberine, or palmatine at the indicated concentrations." (lines 646-650).

Attachment

Submitted filename: Rebuttal Hanh et al.docx

Decision Letter 1

Michael Klymkowsky

25 Oct 2023

Testing biological actions of medicinal plants from northern Vietnam on zebrafish embryos and larvae: developmental, behavioral, and putative therapeutical effects.

PONE-D-23-05393R1

Dear Dr. Muller,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Michael Klymkowsky, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: My thanks to the authors for carefully addressing all reviewer comments. The Discussion is much improved and I appreciate the effort made to answer my suggested questions.

My feedback is minor

1. The introduction needs proofreading – please see attached pdf for my suggestions

2. In the version I can see, the ‘concentration’ title in figure 7B obstructs the numbers on the X axis. This may be addressed later in your proofs.

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Siobhan Crilly

Reviewer #2: No

**********

Attachment

Submitted filename: PONE-D-23-05393_R1_reviewer_SC.pdf

Acceptance letter

Michael Klymkowsky

30 Oct 2023

PONE-D-23-05393R1

Testing biological actions of medicinal plants from northern Vietnam on zebrafish embryos and larvae: developmental, behavioral, and putative therapeutical effects.

Dear Dr. Muller:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Michael Klymkowsky

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Survival curves for each experimental day upon treatment with 6 different medicinal plant extracts.

    (TIF)

    S2 Fig. HPLC chromatograms of M. bealei extract.

    HPLC chromatograms of M. bealei extract and in-house reference compounds, including jatrorrhizine, isotetradine, 3-hydroxy-8-oxopalmatine, 8-oxypalmatine, oxyberberine, rugosinone, 8-oxyberberrubine, berberine, and palmatine.

    (TIF)

    S3 Fig. Extended chromatograms of M. bealei extracts.

    Extended chromatograms (-6 to 16 mAu) of M. bealei extract, jatrorrhizine, isotetradine, 3-hydroxy-8-oxopalmatine, 8-oxypalmatine, oxyberberine, rugosinone, and 8-oxyberberrubine. Matched compounds (jatrorrhizine, isotetradine, 8-oxypalmatine, oxyberberine, and 8-oxyberberrubine) are marked on the chromatogram of the extract.

    (TIF)

    S4 Fig. Structures of the compounds detected in M. bealei extract.

    (TIF)

    S1 Table. Differentially expressed genes (DEGs) at 10hpf upon treatment with KT09.

    (XLSX)

    S2 Table. Genes most affected by KT09 treatment.

    (DOCX)

    S3 Table. GSEA-GO-term analysis of DEGs.

    (DOCX)

    S4 Table. All enrichment analyses.

    ORA indicates "Over-Representation analysis" using UP- or DOWN-regulated genes, GSEA indicates ’Gen Set Enrichment Analysis", used databases were GO, KEGG, Panther, Reactome, Wikipathways, and a home-made zebrafish mutant gene-phenotype list, "description" and "size" gives the name and size of the corresponding term, "overlap" indicates the number of genes in the dataset, "enrichmentRatio" indicates the enrichment factor in the term, while pValue and FDR (False Discovery Rate) indicate the statistical significance of the enrichment, "userId" holds the list of the overlapping genes in the dataset.

    (XLSX)

    S5 Table. Genes whose mutation affects selected processes.

    (XLSX)

    Attachment

    Submitted filename: Rebuttal Hanh et al.docx

    Attachment

    Submitted filename: PONE-D-23-05393_R1_reviewer_SC.pdf

    Data Availability Statement

    Data relevant to this study are available from NCBI's Gene Expression Omnibus at GEO Series accession number GSE207770.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES